Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period ended March 31, 2024


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-56364

Charlotte's Web Holdings, Inc.

(Exact name of registrant as specified in its charter)


British Columbia									98-1508633
(State or other jurisdiction of incorporation or organization)									(I.R.S. Employer Identification No.)

700 Tech Court

Louisville, CO 80027

(Address of principal executive offices and zip code)

(720) 484-8930

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Securities registered pursuant to section 12(g) of the Act:

Common stock, no par value

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

The registrant had outstanding 157,227,855 shares of common shares as of May 6, 2024.

CHARLOTTE'S WEB HOLDINGS, INC.

FORM 10-Q

For the Quarter Ended March 31, 2024

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS




Part I	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements (Unaudited)	1
	- Condensed Consolidated Balance Sheets	2
	- Condensed Consolidated Statements of Operations	3
	- Condensed Statements of Changes in Shareholders' Equity	4
	- Condensed Consolidated Statements of Cash Flows	5
	- Notes to Condensed Consolidated Financial Statements	6
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3.	Quantitative and Qualitative Disclosures about Market Risk
Item 4.	Controls and Procedures
Part II	OTHER INFORMATION
Item 1.	Legal Proceedings
Item 1A.	Risk Factors
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.	Defaults Upon Senior Securities
Item 4.	Mine Safety Disclosures
Item 5.	Other Information
Item 6.	Exhibits
	SIGNATURES

PART I

Item 1. Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)


	March 31,		December 31,
	2024 (unaudited)		2023
ASSETS
Current assets:
Cash and cash equivalents	$	38,510	$	47,820
Accounts receivable, net	1,725		1,950
Inventories, net	22,487		21,538
Prepaid expenses and other current assets	5,535		6,864
Total current assets	68,257		78,172
Property and equipment, net	28,255		27,513
License and media rights	17,614		17,070
Operating lease right-of-use assets, net	14,206		14,601
Investment in unconsolidated entity	10,200		11,000
SBH purchase option and other derivative assets	1,579		2,602
Intangible assets, net	1,051		887
Other long-term assets	616		703
Total assets	$	141,778	$	152,548
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3,991	$	2,860
Accrued and other current liabilities	8,230		8,682
Lease obligations – current	2,339		2,252
License and media rights payable - current	5,072		9,852
Total current liabilities	19,632		23,646
Convertible debenture	42,736		42,528
Lease obligations	15,063		15,655
License and media rights payable	13,899		11,338
Derivative and other long-term liabilities	3,780		3,823
Total liabilities	95,110		96,990
Commitments and contingencies (Note 7)
Shareholders’ equity:
Common shares, nil par value; unlimited shares authorized; 157,227,855 and 154,332,366 shares issued and outstanding as of March 31, 2024 and December 31, 2023	1		1
Additional paid-in capital	328,024		327,280
Accumulated deficit	(281,357)		(271,723)
Total shareholders’ equity	46,668		55,558
Total liabilities and shareholders’ equity	$	141,778	$	152,548

See Notes to Unaudited Condensed Consolidated Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)


	Three Months Ended March 31, (unaudited)
	2024		2023
Revenue	$	12,124	$	17,010
Cost of goods sold	5,213		7,093
Gross profit	6,911		9,917

Selling, general, and administrative expenses	15,280		17,513
Operating loss	(8,369)		(7,596)

Change in fair value of financial instruments	(1,860)		5,382
Other income (expense), net	611		(698)
Loss before provision for income taxes	$	(9,618)	$	(2,912)
Income tax expense	(16)		—
Net loss	$	(9,634)	$	(2,912)

Per common share amounts (Note 10)
Net loss per common share, basic and diluted	$	(0.06)	$	(0.02)

See Notes to Unaudited Condensed Consolidated Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands, except share amounts)

(unaudited)


	Common Shares			Additional Paid-in Capital		Accumulated Deficit		Total Shareholders’ Equity
	Shares	Amount
Balance—December 31, 2023	154,332,366	$	1	$	327,280	$	(271,723)	$	55,558
Common shares issued upon vesting of restricted share units, net of withholding	2,895,489	—		(98)		—		(98)
Share-based compensation	—	—		842		—		842
Net loss		—				(9,634)		(9,634)
Balance—March 31, 2024	157,227,855	$	1	$	328,024	$	(281,357)	$	46,668

Balance—December 31, 2022	152,135,026	$	1	$	325,431	$	(247,927)	$	77,505
Common shares issued upon vesting of restricted share units, net of withholding	297,888	—		(69)		—		(69)
Share-based compensation	—	—		375		—		375
Net loss	—	—		—		(2,912)		(2,912)
Balance—March 31, 2023	152,432,914	$	1	$	325,737	$	(250,839)	$	74,899

See Notes to Unaudited Condensed Consolidated Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)


	Three Months Ended March 31, (unaudited)
	2024		2023
Cash flows from operating activities:
Net loss	$	(9,634)	$	(2,912)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,493		3,792
Change in fair value of financial instruments	1,860		(5,351)
Convertible debenture and other accrued interest	1,015		697
Share-based compensation	842		375
Changes in right-of-use assets	443		493
Other	(956)		768
Changes in operating assets and liabilities:
Accounts receivable, net	98		(1,212)
Inventories, net	(1,026)		1,187
Prepaid expenses and other current assets	150		480
License and media rights	(2,500)		(2,000)
Operating lease obligations	(551)		(925)
Accounts payable, accrued and other liabilities	663		(1,098)
Other operating assets and liabilities, net	(76)		(367)
Net cash used in operating activities	(7,179)		(6,073)
Cash flows from investing activities:
Purchases of property and equipment and intangible assets	(2,060)		(70)
Proceeds from sale of assets	27		30
Net cash used in investing activities	(2,033)		(40)
Cash flows from financing activities:
Other financing activities	(98)		(69)
Net cash used in financing activities	(98)		(69)
Net decrease in cash and cash equivalents	(9,310)		(6,182)
Cash and cash equivalents —beginning of period	47,820		66,963
Cash and cash equivalents —end of period	$	38,510	$	60,781

Non-cash activities:
Non-cash purchase of property and equipment and intangible assets	$	(374)	$	—

See Notes to Unaudited Condensed Consolidated Financial Statements

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

1. DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS

Description of the Business

Charlotte's Web Holdings, Inc. together with its subsidiaries (collectively "Charlotte's Web" or the "Company") is a public company incorporated pursuant to the laws of the Province of British Columbia and is also a Certified B Corp. The Company's common shares are publicly listed on the Toronto Stock Exchange ("TSX") under the symbol "CWEB" and quoted on the OTCQX under the symbol "CWBHF." The Company's corporate headquarters is located in Louisville, Colorado in the United States of America. The majority of the Company's business is conducted in the United States of America.

The Company's primary products are made from proprietary strains of whole-plant hemp extracts containing a full spectrum of phytocannabinoids, terpenes, flavonoids, and other hemp compounds. Hemp extracts are produced from the plant Cannabis sativa L. ("Cannabis"), and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol ("THC") concentration of not more than 0.3% on a dry weight basis ("Hemp"). The Company is engaged in research involving the effectiveness of a broad variety of compounds derived from Hemp. The Company does not currently produce or sell medical or recreational marijuana or products derived from high THC Cannabis plants. The Company does not currently have any plans to expand into such high THC products in the near future.

The Company's product categories include full spectrum hemp extract oil tinctures (liquid product), gummies, capsules, CBD topical creams and lotions, and pet products. The Company's products are distributed through its e-commerce website, third-party e-commerce websites, select distributors, health practitioners, and a variety of brick-and-mortar specialty retailers.

The Company grows its proprietary hemp domestically in the United States on farms leased in northeastern Colorado and sources hemp through contract farming operations in Arizona, Kentucky, Oregon, and Canada. The Hemp grown in Canada is utilized exclusively in the Canadian markets or for research purposes and not in products sold within the United States.

In furtherance of the Company's research and development ("R&D") efforts, the Company established CW Labs, an internal division for R&D, to expand the Company's efforts around the science of hemp derived compounds. CW Labs is currently engaged in clinical trials addressing Hemp-based health solutions. CW Labs is located in Louisville, Colorado at the Company's current good manufacturing practice ("cGMP") production and distribution facility.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB").

In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company's financial position as of March 31, 2024 and its results of operations for the three months ended March 31, 2024 and 2023, cash flows for the three months ended March 31, 2024 and 2023, and stockholders’ equity for the three months ended March 31, 2024 and 2023. Operating results for the three months ended March 31, 2024, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024. The unaudited interim condensed consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual consolidated financial statements. Certain amounts presented in prior periods have been reclassified to conform with the current period presentation. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2023, included in the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2024.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

Inventories

Inventories are stated at the lower of cost or net realizable value. The Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. The Company's inventory production process for cannabinoid products includes the cultivation of botanical raw material. Due to the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset.

Revenue Recognition

The majority of the Company's revenue is derived from sales of branded products to consumers via the Company's direct-to-consumer e-commerce website, as well as distributors, retail and wholesale business-to-business customers. Additionally, on February 12, 2024, the Company and DeFloria LLC ("DeFloria") entered into a Master Services Agreement ("Services Agreement") pursuant to which the Company is compensated for the provision of certain services to DeFloria. Refer to Note 3 for additional disclosure on the DeFloria Service Agreement. The following table sets forth the disaggregation of the Company's revenue:


	Three Months Ended March 31,
	2024		2023
Direct-to-consumer	$	7,772	$	11,268
Business-to-business	4,041		5,742
Service revenue	311		—
Total revenue	$	12,124	$	17,010

Substantially all of the Company's revenue is earned in the United States.

Recently Adopted Accounting Pronouncements

There are no new accounting pronouncements adopted by the FASB that had or may have a material impact on the accompanying unaudited interim condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

Other than described below, no new accounting pronouncements issued by the Financial Accounting Standards Board ("FASB") may have a material impact on the Company's consolidated financial statements and related disclosures.

On December 14, 2023, the FASB issued a final standard on improvements to income tax disclosures, ASU 2023-09, Improvements to Income Tax Disclosures. The standard requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. For public business entities, the new requirements will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact, if any, that the updated standard will have on the Company's consolidated financial statements and related disclosures.

On November 27, 2023, the FASB issued ASU 2023-07—Segment Reporting. The new guidance was issued primarily to provide financial statement users with more disaggregated expense information about a public entity's reportable segments. The guidance is effective for calendar year public entities in 2024 year-end financial statements and should be adopted retrospectively unless impracticable. The Company is currently evaluating the impact, if any, that the updated standard will have on the Company's consolidated financial statements and related disclosures

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

3. FAIR VALUE MEASUREMENT

The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis at March 31, 2024 and December 31, 2023, by level within the fair value hierarchy:


	March 31, 2024
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	779	$	779
Debt interest rate conversion feature	—		—		800		800
Total financial assets	$	—	$	—	$	1,579	$	1,579

Investment in unconsolidated entity:	$	—	$	—	$	10,200	$	10,200

Financial liabilities:
Debt conversion option	$	—	$	3,200	$	—	$	3,200


	December 31, 2023
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	1,730	$	1,730
Debt interest rate conversion feature	—		—		872		872
Total financial assets	$	—	$	—	$	2,602	$	2,602

Investment in unconsolidated entity:	$	—	$	—	$	11,000	$	11,000

Financial liabilities:
Debt conversion option	$	—	$	3,213	$	—	$	3,213

There were no transfers between levels of the hierarchy during the three months ended March 31, 2024, and the year ended December 31, 2023.

Investment in Unconsolidated Entity

On April 6, 2023, the Company jointly formed an entity, DeFloria, with AJNA BioSciences PBC ("AJNA"), and a subsidiary of British American Tobacco PLC (LSE: BATS and NYSE: BTI) ("BAT"). AJNA is a botanical drug development company. AJNA is partially owned and was co-founded by a co-founder of Charlotte's Web. The entity was established to pursue FDA-approval for a botanical drug to target a neurological condition.

BAT holds an equity interest in DeFloria in the form of 200,000 or 100% preferred units following its $10 million investment and has the right to participate in future equity issuances to maintain its pro rata equity position. Effective February 12, 2024, BAT invested an additional $3 million into DeFloria in exchange for a convertible debenture. The Company and AJNA each hold 400,000 or 50%, respectively, of DeFloria's voting common units. The Company's contribution to DeFloria is a license permitting the use of certain proprietary hemp intellectual property, including clinical and consumer data. Additionally, the Company has a supply agreement with DeFloria, under which the Company supplies the oils at cost used to produce and develop the new drug. AJNA's contribution to the entity is laboratory and regulatory services, clinical expertise, and the provision of clinical services. DeFloria is expected to use the investments for the clinical development of a hemp botanical Investigational New Drug application and has commenced Phase I clinical development.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

Concurrently with the formation of DeFloria, the Company was issued a warrant to purchase 865,052 shares of Class A Common Stock of AJNA for an exercise price of $2.89 per share. Management determined the warrant should be accounted for in accordance with ASC 321, which requires the warrant to be measured at fair value at issuance and subsequently remeasured at fair value each reporting period. All changes from the remeasurement of the warrant will be recorded as a change in fair value of financial instruments in the condensed consolidated statements of operations. The Company determined the fair value of the AJNA warrants to be de minimis and as such no value was recorded as of March 31, 2024.

The Company determined that it has a variable interest in the investment in DeFloria; however, the Company is not the primary beneficiary of DeFloria as it lacks the power to direct DeFloria's key activities. The Company concluded that the investment in DeFloria should not be consolidated. The maximum exposure to loss in the investment in DeFloria is limited to the Company's investment, which is represented by the financial statement carrying amount of its retained interest.

In accordance with ASC 825-10, equity method investments are eligible for the fair value option as they represent recognized financial assets. As the Company is not required to consolidate the investment and does not meet any of the other scope exceptions, the Company had the ability to adopt the fair value option for the investment at inception. Upon formation of the entity, the Company elected the fair value option because it allowed the investment to be valued based on current market conditions. As such, the investment has been remeasured at fair value at each reporting date, with changes recognized in condensed consolidated statements of operations as changes in fair value of financial instruments for the period. For the three months ended March 31, 2024, a loss of $800, respectively, related to the investment in DeFloria was recognized as a change in fair value of financial instruments in the condensed consolidated statements of operations. As of March 31, 2024 and December 31, 2023, the DeFloria investment represents an investment of $10,200 and $11,000 within the condensed consolidated balance sheets.

The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. To determine the value of the investment, the Company utilizes an Option Pricing Model (OPM). The OPM considers the various terms of the stockholder agreements, including the level of seniority among the securities, dividend policy, conversion ratios, and cash allocations upon liquidation of the entity. The OPM is appropriate when the range of potential future outcomes is difficult to predict with any certainty.

The following additional assumptions are used in the model:


	March 31,	December 31,
	2024	2023
Expected term (years)	6.0	6.3
Volatility	75.0%	70.0%
Risk-free interest rate	4.2%	3.9%
Expected dividend yield	—%	—%
Discount for lack of marketability	20.0%	20.0%

Convertible Debt Derivatives

On November 14, 2022, the Company entered into a subscription agreement (the "Subscription Agreement") with BT DE Investments, Inc. a wholly-owned subsidiary of BAT Group (LSE: BATS and NYSE: BTI) (the "Lender"), providing for the issuance of $56.8 million (C$75.3 million) convertible debenture (the "debenture"). The debenture is convertible into 19.9% ownership of the Company's common shares at a conversion price of C$2.00 per common share of the Company on the TSX. The debenture will accrue interest at a stated annualized rate of 5% until such time that there is federal regulation permitting the use of cannabidiol, a phytocannabinoid derived from the plant Cannabis sativa L. ("CBD") as an ingredient in food products and dietary supplements in the United States. (The term "federal regulation" is defined as the date that federal laws in the United States permit, authorize or do not prohibit the use of CBD as an ingredient

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

in food products and dietary supplements). Following federal regulation of CBD, the annualized rate of interest shall reduce to 1.5%. The maturity date for the debenture is November 14, 2029 (the "Maturity Date").

Debt Interest Rate Conversion Feature

The debt interest rate conversion feature is classified as a financial asset and is remeasured at fair value at each reporting date, with changes recognized in condensed consolidated statements of operations as changes in fair value of financial instruments for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. The debt interest rate conversion feature, if triggered, reduces the stated interest rate of the debenture to 1.5% upon federal regulation of CBD in the United States.

For the three months ended March 31, 2024 and March 31, 2023, a loss of $54 and $605, respectively, related to the debt interest rate conversion feature was recognized as a change in fair value of financial instruments in the condensed consolidated statements of operations. As of March 31, 2024 and December 31, 2023, the debt interest rate conversion feature represents a financial asset of $800 and $872, respectively, within SBH purchase option and other derivative assets in the condensed consolidated balance sheets.

To determine the value of the debt interest rate conversion feature, the Company utilizes a probability weighted income approach. This method calculates the present value of the reduced interest accrued on the debenture assuming the feature is triggered at a certain time, after accounting for the probability of federal regulation of CBD. This approach is useful when ultimate valuation is based on an unverifiable outcome, such as an event outside of the Company's influence. The following additional assumptions are used in the model:


	March 31,	December 31,
	2024	2023
Stated interest rate	5.0%	5.0%
Adjusted interest rate	1.5%	1.5%
Implied debt yield	12.8%	11.0%
Federal regulation probability	Various	Various
Year of event	Various	Various

Debt Conversion Option

Per the debenture, the Lender has the option, at any time before the Maturity Date at no additional consideration, for all or any part of the principal amount to be converted into fully paid and non-assessable common shares. The Company assessed this conversion feature and determined that the debt conversion option is an embedded derivative that requires bifurcation and is classified as a financial liability. The debt conversion option is initially measured at fair value and is revalued at each reporting period using the Black-Scholes option pricing model based on Level 2 observable inputs. The assumptions used by the Company are the quoted price of the Company's common shares in an active market, risk-free interest rate, volatility and expected life, and assumes no dividends. Volatility is based on the actual historical market activity of the Company's shares. The expected life is based on the remaining contractual term of the debenture and the risk-free interest rate is based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the expected maturity of the debenture.

For the three months ended March 31, 2024 and March 31, 2023, a loss of $56 and a gain of $6,257, respectively, related to the debt conversion option was recognized as a change in fair value of financial instruments in the condensed consolidated statements of operations. As of March 31, 2024 and December 31, 2023, the debt conversion option represents a financial liability of $3,200 and $3,213, respectively, within derivative and other long-term liabilities in the condensed consolidated balance sheets.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

The following table provides the assumption regarding Level 2 fair value measurements inputs at their measurement dates:


	March 31,	December 31,
	2024	2023
Expected volatility	87.9%	87.4%
Expected term (years)	5.6	5.9
Risk-free interest rate	4.2%	3.9%
Expected dividend yield	—%	—%
Value of underlying share	C$0.28	C$0.27
Exercise price	C$2.00	C$2.00

Stanley Brothers USA Holdings Purchase Option

In 2021, the Company entered into an option purchase agreement (the "SBH Purchase Option") with Stanley Brothers USA Holdings, Inc ("Stanley Brothers USA") . The SBH Purchase Option was purchased for total consideration of $8,000 and has a term of five years (extendable for an additional two years upon payment of additional consideration). The SBH Purchase Option provides the Company the option to acquire all or substantially all the shares of Stanley Brothers USA on the earlier of February 26, 2024 and federal legalization of cannabis in the United States, or such earlier time as Stanley Brothers USA and the Company agree, at a purchase price to be determined at the time of exercise of the SBH Purchase Option. Upon exercise of the SBH Purchase Option, the purchase price will be determined based on application of predetermined multiples of Stanley Brothers USA revenue and earnings before interest, taxes, depreciation, and amortization ("EBITDA") measures. The Company is not obligated to exercise the SBH Purchase Option. As part of the SBH Purchase Option agreement, Stanley Brothers USA issued the Company a warrant exercisable to purchase 10% of the outstanding Stanley Brothers USA shares and convertible securities that are considered in-the-money, subject to certain conditions and exclusions. The warrant is exercisable at the Company's election for a nominal exercise price in the event the Company elects not to acquire all or substantially all shares of Stanley Brothers USA and expires 60 days after the expiration of the option.

The Company elected the fair value option in accordance with ASC 825-10 guidance to record its SBH Purchase Option. The SBH Purchase Option is classified as a financial asset and is remeasured at fair value at each reporting date, with changes to fair value recognized in the condensed consolidated statements of operations for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows. For the three months ended March 31, 2024 and 2023, a loss of $951 and $300, respectively, related to the SBH Purchase Option was recognized as change in fair value of financial instruments in the condensed consolidated statements of operations. As of March 31, 2024 and December 31, 2023, the SBH Purchase Option represents a financial asset of $779 and $1,730, respectively, within SBH purchase option and other derivative assets in the condensed consolidated balance sheets.

The Monte Carlo valuation model considers multiple revenue and EBITDA outcomes for Stanley Brothers USA and other probabilities in assigning a fair value. Primary assumptions utilized include financial projections of Stanley Brothers USA and the probability and timing of exercise. The following additional assumptions are used in the model of the SBH Purchase Option:


	March 31,	December 31,
	2024	2023
Expected volatility	125.0%	125.0%
Expected term (years)	1.9	2.2
Risk-free interest rate	4.6%	4.2%
Weighted average cost of capital	50.9%	50.6%

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

4. INVENTORIES

Inventories consist of the following:


	March 31,		December 31,
	2024		2023
Harvested Hemp and seeds	$	8,736	$	9,300
Raw materials	10,637		9,726
Finished goods	6,668		6,320
	26,041		25,346
Less: inventory provision	(3,554)		(3,808)
Total	$	22,487	$	21,538

5. LICENSE AND MEDIA RIGHTS

MLB Promotion Rights Agreement

On October 11, 2022, the Company entered into a Promotional Rights Agreement (the "MLB Promotional Rights Agreement") with MLB Advanced Media L.P., on its own behalf and on behalf of Major League Baseball Properties, Inc., the Office of the Commissioner of Baseball, The MLB Network, LLC and the Major League Baseball Clubs (collectively, the "MLB"), pursuant to which the Company entered into a strategic partnership with MLB to promote the Company's new NSF-Certified for Sport® product line. On January 29, 2024, the Company and MLB entered into the First Amendment to the Promotional Rights Agreement ("First Amendment"). The First Amendment extended the agreement through December 31, 2027, with an aggregate rights fee of $23 million for the remainder of the term.

As consideration under the MLB promotional rights agreement, the Company has paid and is committed to pay a combination of cash over the license period, along with upfront non-cash consideration in the form of equity, as well as contingent consideration in the form of contingent payments based on revenue.

As of March 31, 2024 and December 31, 2023, the carrying value of the licensed properties was $14,614 and $14,589, respectively, recorded as a license and media rights asset within the condensed consolidated balance sheets. As of March 31, 2024 and December 31, 2023, the carrying value of the media rights was $4,000 and $4,982 recorded as a prepaid asset and a license and media rights asset within the condensed consolidated balance sheets. For the three months ended March 31, 2024 and March 31, 2023, the Company paid the MLB $2,500 and $2,000, respectively, as part of the committed cash payments, and recognized $974 and $1,824, respectively, in amortization expense related to the license and media right assets. Licensed properties are amortized straight line and media rights are amortized as incurred.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

The MLB First Amendment agreement extended the maturities of the future payment by an additional 2 years. Maturities of the MLB license and media rights payable as of March 31, 2024 are as follows:


2024 (9 months remaining)	$	2,500
2025	5,500
2026	6,000
2027	6,500
Total payments	$	20,500
Less: Imputed interest	(1,529)
Total license and media rights payable	$	18,971
Less: Current license liabilities	(5,072)
Total non-current license and media rights payable	$	13,899

As of March 31, 2024, expected amortization of licensed properties are as follows:


2024 (9 months remaining)	$	2,923
2025	3,897
2026	3,897
2027	3,897
Total future amortization	$	14,614

6. DEBT

Convertible Debenture

On November 14, 2022, the Company entered into the Subscription Agreement with BT DE Investments, Inc., providing for the issuance of a $56.8 million (C$75.3 million) convertible debenture. The debenture was denominated in Canadian Dollars ("CAD" or "C$"). The debenture is convertible into 19.9% ownership of the Company's common shares at a conversion price of C$2.00 per common share of the Company. The debenture will accrue interest at a stated annualized rate of 5% until such time that there is federal regulation permitting the use of CBD as an ingredient in food products and dietary supplements in the United States. Following federal regulation of CBD, the stated annualized rate of interest shall reduce to 1.5%. Interest is accrued annually and payable on the maturity date or date of earlier conversion. The maturity date for the debenture is November 14, 2029.

The following is a summary of the Company's convertible debenture as of March 31, 2024:


	As of March 31, 2024
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	59,544	$	(16,808)	$	42,736

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

The following is a summary of the Company's convertible debenture as of December 31, 2023:


	As of December 31, 2023
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	60,116	$	(17,588)	$	42,528

The debenture was C$75.3 million per the subscription agreement and translated to USD on the transaction date. For the three months ended March 31, 2024 and March 31, 2023, the Company recognized a foreign currency gain of $925 and $12, respectively, related to the net carrying value of the debenture within the condensed consolidated statements of operations.

Interest is accrued annually and payable on the maturity date or date of earlier conversion. On conversion, accrued interest will either be converted into common shares equal to the amount of accrued interest or will be paid in cash if agreed with the Lender. As of March 31, 2024 and December 31, 2023, the principal amount of the debenture includes $3,915 and $3,182, respectively, of accrued interest expense. The following is a summary of the interest expense and amortization expense, recorded within the condensed consolidated statements of operation, of the Company's convertible debenture for the three months ended March 31, 2024:


	Three Months Ended March 31,
	2024		2023
Interest expense	$	733	$	697
Amortization of debt discounts and costs	401		319
Total interest and amortization expense	$	1,134	$	1,016

7. COMMITMENTS AND CONTINGENCIES

Legal Contingencies

From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of March 31, 2024 there is no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company’s financial position, results of operations or cash flows.

8. LEASES

The Company has lease arrangements related to office space, warehouse and production space, and land to facilitate agricultural operations. The leases have remaining lease terms of less than one to eleven years, some of which include options to extend the leases for up to five years. Generally, the lease agreements do not include options to terminate the lease.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

Maturities of operating lease liabilities as of March 31, 2024 are as follows:


	Operating Leases
2024 (9 months remaining)	$	2,449
2025	2,892
2026	2,169
2027	1,844
2028	1,762
Thereafter	11,884
Total lease obligation	23,000
Less: Imputed interest	(5,598)
Total lease liabilities	17,402
Less: Current lease liabilities	2,339
Total non-current lease liabilities	$	15,063

9. SHAREHOLDERS’ EQUITY

As of March 31, 2024 and December 31, 2023, the Company's share capital consists of one class of issued and outstanding shares: common shares. The Company is also authorized to issue preferred shares issuable in series. To date, no shares of preferred shares have been issued or are outstanding.

Common Shares

As of March 31, 2024 and December 31, 2023, the Company was authorized to issue an unlimited number of common shares, which have no par value.

10. LOSS PER SHARE

The Company computes loss per share of common shares. Basic net loss per common share is computed by dividing the net loss by the weighted-average number of common shares outstanding. Diluted loss per common share is computed by dividing the net loss by the weighted-average number of common shares together with the number of additional common shares that would have been outstanding if all potentially dilutive common shares had been issued, unless anti-dilutive.

The following table sets forth the computation of basic and dilutive net loss per share attributable to common shareholders:


	Three Months Ended March 31,
	2024		2023
Net loss	$	(9,634)	$	(2,912)
Weighted-average number of common shares - basic	156,036,670		152,314,150
Dilutive effect of stock options and awards	—		—
Weighted-average number of common shares - diluted	156,036,670		152,314,150
Loss per common share – basic and diluted	$	(0.06)	$	(0.02)

As of March 31, 2024 and March 31, 2023, potentially dilutive securities include stock options, restricted share units, common share warrants, and convertible debenture conversion. When the Company recognizes a net loss from continuing operations, all potentially

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

dilutive shares are anti-dilutive and are consequently excluded from the calculation of diluted net loss per share. The potentially dilutive awards outstanding for each period are presented in the table below:


	March 31,
	2024	2023
Outstanding options	5,522,942	4,386,215
Outstanding restricted share units	3,750,000	2,216,022
Total	9,272,942	6,602,237

The Company's debenture is convertible into 19.9% ownership of the Company's common shares at a conversion price of C$2.00 per common share of the Company. The Company can settle the convertible debenture in shares. If the convertible debenture in diluted EPS is anti-dilutive, or if the conversion value of the debenture does not exceed their conversion price for a reporting period, then the shares underlying the notes will not be reflected in the Company's calculation of diluted EPS. For the three months ended March 31, 2024, the price of the Company's shares did not exceed the conversion price and therefore there was no impact to potential common share diluted EPS during those periods.

11. SHARE-BASED COMPENSATION

Stock options

Stock options vest over a prescribed service period and are approved by the Company's board of directors on an award-by-award basis. Options have a prescribed service period generally lasting up to four years, with certain options vesting immediately upon issuance. Upon the exercise of any stock options, the Company issues shares to the award holder from the pool of authorized but unissued common shares.

There were no options granted for the three months ended March 31, 2024. The fair values of options granted for the three months ended March 31, 2023 were determined using a Black-Scholes model. The following principal inputs were used in the valuation of awards issued for the three months ended March 31, 2023:


	Three Months Ended March 31,
		2023
Expected volatility		89.5%
Expected term (years)		5.5-6.5
Risk-free interest rate		3.4%
Expected dividend yield		0%
Value of underlying share		$0.56

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

Detail of the number of stock options outstanding for the three months ended March 31, 2024 under the Company's 2015 legacy option plan and the Company's amended 2018 long term incentive plan (collectively, the "Plans") is as follows:


	Number of Options	Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contract Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	5,780,134	$	0.75	8.56	$	—
Granted	—	—
Exercised	—	—
Forfeited (and expired)	(257,192)	0.53
Outstanding as of March 31, 2024	5,522,942	$	0.77	8.31	$	—

Exercisable/vested as of March 31, 2024	2,761,000	$	1.06	7.39	$	—

There were no options granted during the three months ended March 31, 2024. The weighted average grant-date fair value of options granted during the three months ended March 31, 2023 was $0.56.

There were no options exercised during the three months ended March 31, 2024 and 2023.

Restricted share units

The Company has issued time-based restricted share units to certain employees as permitted under the amended 2018 long term incentive plan ("the 2018 Plan"). The restricted share units granted vest in accordance with the board-approved agreement, typically over equal installments up to four years. Upon vesting, one common share of the Company is issued for each restricted share unit awarded. The fair value of each restricted share unit granted is equal to the market price of the Company's shares at the date of the grant. The fair value of shares vested during the three months ended March 31, 2024 and 2023 was $869 and $740, respectively.

Details of the number of restricted share units outstanding under the 2018 Plan is as follows:


	Number of Shares	Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2023	7,250,766	$	0.31
Granted	—	$	—
Forfeited	(85,731)	$	0.53
Vested	(2,895,489)	$	0.30
Shares withheld upon vesting	(519,546)	$	0.53
Outstanding as of March 31, 2024	3,750,000	$	0.29

Share-based Compensation Expense

Share-based compensation expense for all equity arrangements for the three months ended March 31, 2024 and 2023 was $842 and $375, respectively, included in selling, general and administrative expense in the condensed consolidated statements of operations. As of March 31, 2024, $1,783 of total unrecognized share-based compensation expense related to unvested options granted to employees is expected to be recognized over a weighted-average period of 2.25 years.

CHARLOTTE’S WEB HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share, per share, per unit, and number of years)

(unaudited)

12. INCOME TAXES

The Company reported income tax expense of $16 and $0 for the three months ended March 31, 2024 and 2023, respectively. The Company's effective tax rate in the three months ended March 31, 2024 and 2023 was (0.2)% and 0%, respectively. The Company's effective tax rates differ from the U.S. federal statutory rate of 21.0% for the three months end March 31, 2024 and 2023, respectively, primarily due to the valuation allowance. The effective tax rate for the three months ended March 31, 2024 is consistent with the three months ended March 31, 2023, as the Company has been in a full valuation allowance for both periods.

13. RELATED PARTY TRANSACTIONS

Effective November 2020, the Company issued a secured promissory note, where $1,000 was loaned to one of the Company's founders. The note receivable was secured by equity instruments with certain founders of the Company, bore interest at 3.25% per annum, and required the unpaid principal and unpaid interest balances to be paid on or before the maturity date of November 13, 2021. Effective December 28, 2023, the Company entered into a second amendment of the promissory note to extend the maturity date until November 13, 2024. According to the terms of the agreement, no additional interest will accrue through the payment date. The note has been fully reserved for as of December 31, 2023.

On March 2, 2021, the Company entered into the SBH Purchase Option with Stanley Brothers USA as discussed above (Note 3 "Fair Value Measurement"). The SBH Purchase Option was purchased for total consideration of $8,000. Certain founders of the Company, who are or were employees at the time, are the majority shareholders of Stanley Brothers USA.

On April 6, 2023, the Company jointly formed an entity, DeFloria, with AJNA and BAT. AJNA is a botanical drug development company. AJNA is partially owned and was co-founded by a co-founder of Charlotte's Web. BAT holds an equity interest in the entity in the form of 200,000 preferred units following its $10 million investment and has the right to participate in future equity issuances to maintain its pro rata equity position. The Company and AJNA each hold 400,000 of the entity's voting common units (Note 3). Effective May 1, 2023, the Company entered into an 8% interest bearing note receivable with DeFloria for the sale of lab equipment in the amount of $170. The principal and interest of the note receivable will be paid in 36 monthly installments. As of March 31, 2024, the remaining note receivable of $113 is presented in other assets in the condensed consolidated balance sheets. On February 12, 2024, BAT invested an additional $3 million in DeFloria in the form of convertible debt (refer to Note 3). Additionally on February 12, 2024, the Company and DeFloria entered into a separate master services agreement pursuant to which the Company will be compensated for the provision of certain services to DeFloria. For the three months ended March 31, 2024, the Company recognized $311 in revenue and cost of goods sold, respectively, related to the service agreement with DeFloria. Additionally, the Company has an accounts receivable balance due from DeFloria of $74 for the three months ended March 31, 2024.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward Looking Statements

This Quarterly Report on Form 10-Q ("Form 10-Q") contains statements that are, or may be considered to be, "forward-looking statements" under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions. All statements other than statements of historical fact included in this Form 10-Q regarding the prospects of Charlotte's Web Holdings, Inc. ("Charlotte's Web", the "Company" or "we"), the industry or its prospects, plans, financial position or business strategy may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as "plans," "expects" or "does not expect," "is expected," "look forward to," "budget," "scheduled," "estimates," "forecasts," "will continue," "intends," "the intent of," "have the potential," "anticipates," "does not anticipate," "believes," "should," "should not," or variations of such words and phrases that indicate that certain actions, events or results "may," "could," "would," "might," or "will," "be taken," "occur," or "be achieved," or the negative of these terms or variations of them or similar terms. Furthermore, forward-looking statements may be included in various filings that the Company makes with the SEC, on SEDAR+, or in press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. All capitalized and undefined terms used in this section shall have the same meanings hereafter defined in this Quarterly Report on Form 10-Q.

The following discussion and analysis of financial condition and results of operations should be read in conjunction with, and is qualified in its entirety by, the unaudited condensed consolidated financial statements and the accompanying notes in this Form 10-Q and the sections entitled "Item 1A. Risk Factors" and "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2023. Except for historical information, the discussion in this section contains forward-looking statements that involve risks and uncertainties, as discussed in the "Cautionary Note Regarding Forward Looking Statements." Future results could differ materially from those discussed below for many reasons, including the risks described in Item 1A—"Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and in Part II, Item 1A—"Risk Factors" of this Form 10-Q.

Management's Discussion & Analysis of Charlotte's Web Holdings, Inc.

For purposes of this discussion, "Charlotte's Web," "CW," "we," "our", "us", or the "Company" refers to Charlotte's Web Holdings, Inc. and its subsidiaries: Charlotte's Web, Inc. and Abacus Products, Inc., and its wholly-owned subsidiaries: Abacus Health Products, Inc., Abacus Wellness, Inc. and CBD Pharmaceuticals Ltd. The results herein have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

Amounts are presented in thousands of United States dollars, unless otherwise indicated.

BUSINESS OVERVIEW

Charlotte's Web Holdings, Inc. is a Certified B Corp headquartered in Louisville, Colorado, which conducts the majority of its business in the United States. The Company is a market leader in innovative hemp extract wellness products under a family of brands which includes Charlotte's Web™, CBD Medic™, and CBD Clinic™. Charlotte's Web premium quality products start with proprietary hemp genetics that are 100% North American farm grown and are then manufactured into hemp extracts containing naturally occurring phytocannabinoids including CBD, cannabichromene ("CBC"), cannabigerol ("CBG"), terpenes, flavonoids and other cannabinoids and beneficial hemp compounds. The Company is headquartered in a cGMP compliant facility in Louisville, Colorado, where the Company conducts its production of tinctures, distribution, and quality control activities as well as research and development ("R&D"). Charlotte's Web product categories include full spectrum hemp extract oil tinctures (liquid products), gummies, capsules, CBD topical creams and lotions, and pet products. The Company also offers NSF Certified for Sports® broad spectrum tincture and gummy products. Charlotte's Web products are distributed to retailers and health care practitioners, and online through the Company's website at www.CharlottesWeb.com. The information provided on the website is not part of this MD&A.

The Company's business consists of the farming, manufacturing, marketing, and sales of hemp-derived CBD wellness products. As of March 31, 2024, the Company operated in a single operating and reportable segment, hemp-derived CBD wellness products. The executive officers reviewed overall operating results in order to assess financial performance and to make resource allocation decisions, rather than to assess a lower-level unit of operations in isolation.

The Company's primary products are made from proprietary strains of whole-plant hemp extracts containing a full spectrum of phytocannabinoids, terpenes, flavonoids and other hemp compounds. The Company believes the presence of these various compounds work synergistically to heighten the effects of the products, making them superior to single-compound isolates.

Hemp extracts are produced from Cannabis and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a THC concentration of not more than 0.3% on a dry weight basis. The Company is engaged in research involving a broad variety of compounds derived from Hemp. Where research provides evidence that a greater than 0.3% THC level may have a potential therapeutic use, the Company may consider pursuing development of that use in jurisdictions where it is legal to do so in accordance with applicable regulations and if consistent with the Company's founding principles. The Company does not currently have any plans to expand into high THC products in the near future.

Recent Developments

With an increased commitment to innovation, Charlotte's Web has refreshed its mission to "Unearth the Science of Nature to Revolutionize Wellness," and is evolving its wellness offerings both to strengthen our core leadership in CBD, and extend beyond CBD to include a broader range of botanical wellness solutions, including minor cannabinoids. A testament to this expansion is the launch of Charlotte's Web Stay Asleep Cannabinol ("CBN") gummies. Similar to Cannabidiol ("CBD"), CBN is a non-intoxicating cannabinoid found in the hemp plant. At the cutting edge of innovative natural sleep solutions, these new melatonin free gummies could offer distinct benefits for the approximately 67% of adults who report waking up during the night (Phillips Global Sleep Survey, 2019). This is the first CBN sleep product supported by placebo-controlled peer-reviewed research study, offering a 20 mg dose of CBN. The Stay Asleep gummy demonstrates Charlotte's Web's commitment to science-backed products, providing an effective alternative to more traditional sleep supplements and medications. Charlotte's Web believes expanding beyond CBD leverages the Company's brand recognition, intellectual property, and partnerships, including an ongoing collaboration with DeFloria LLC ("DeFloria") for botanical drug development.

During the first quarter of 2024, Charlotte's Web unveiled a significant competitive price reduction of its leading CBD oils, without sacrificing its proprietary formulation or quality. This was accomplished by passing through improved operational efficiencies to consumers, with modest gross margin reduction expected to be offset with additional volume. More affordable pricing improves consumer accessibility, and broadens the total addressable consumer segments, attracting new consumers.

To better leverage its leading brand equity, the Company consolidated its CBD Medic and CBD Clinic brands under a unified Charlotte’s Web brand architecture. Additionally, the Company's ReCreate brand has been absorbed under the recognized Charlotte’s Web brand to better penetrate the lifestyles category. Charlotte’s Web NSF Certified for Sport® will benefit from the Company’s valuable professional sports partnerships, including the Angel City Football Club, U.S. Premier Lacrosse League, and Major League Baseball©.

As of March 31, 2024, several states have adopted new regulations that will impact the Company's ability to sell certain products as currently formulated or packaged in these states. Many of these states have also implemented new THC/CBD limits, age verification, labeling and packaging requirements. The Company continues to assess the business and financial impacts of the new regulations, including steps that can be taken to address the new product formulation, packaging, and labeling requirements, as well as costs and potential revenue impacts and anticipated timing for such impacts to the Company in these states.

The Company continues to invest in R&D efforts to identify new product opportunities. The Company is working to capitalize on the rapidly emerging botanical wellness products industry by driving customer acquisition and retention, as well as accelerating retail expansion. In addition, the Company may consider expanding its product line beyond Hemp-based products should the science and the Company's founding principles support such expansion.

Selected Financial Information


	For the Three Months Ended March 31,
	2024		2023
Total revenues	$	12,124	$	17,010
Cost of goods sold	5,213		7,093
Gross profit	$	6,911	$	9,917
Selling, general, and administrative expenses	15,280		17,513
Operating loss	$	(8,369)	$	(7,596)
Change in fair value of financial instruments	(1,860)		5,382
Other income (expense), net	611		(698)
Net loss	$	(9,634)	$	(2,912)
Total assets	$	141,778	$	175,971
Total liabilities	$	95,110	$	101,072

Revenue

The majority of the Company's revenue is derived from sales of branded products to consumers via the Company's DTC e-commerce website, and distributors, retail and wholesale B2B customers.


	Three Months Ended March 31,				% (Decrease)
		2024				2023
Direct-to-consumer ("DTC") revenue			$	7,772		$	11,268	(31.0)	%
Business-to-business ("B2B") revenue			4,041			5,742		(29.6)	%
Service revenue			311			—		100.0	%
Total revenue			$	12,124		$	17,010	(28.7)	%

Total revenue for the three months ended March 31, 2024 was $12,124, a decrease of 28.7% compared to the three months ended March 31, 2023. DTC e-commerce revenue decreased 31.0% year-over-year. The decrease compared to the prior year period was primarily due to lower organic traffic volume and prior consumers stocking up on product during the heavy holiday promotions in the fourth quarter of 2023. Website traffic and new consumer acquisition was also lower in the quarter due to a temporary reduction in paid media programs as part of an evaluation as the Company transitions its e-commerce platform and associated marketing.

B2B revenue decreased 29.6% compared to the three months ended March 31, 2023.The decrease compared to prior period was primarily due to the reductions in retail shelf space allocated to the CBD category that occurred in 2023. Some of the Company’s mass retail partners fully exited the CBD category, increasing the year-over-year revenue decline.

The decrease in revenue is partially offset by service revenue of $311. On February 12, 2024, the Company and DeFloria entered into a Master Services Agreement ("Services Agreement") pursuant to which the Company is compensated for the provision of certain services to DeFloria.

Cost of Goods Sold

Cost of goods sold includes the cost of inventory sold, changes in inventory provisions, and other production costs expensed. Other production costs include direct and indirect production costs including direct labor, processing, testing, packaging, quality assurance, security, shipping, depreciation of production equipment, indirect labor, including production management, and other related expenses. The primary factors that can impact cost of goods sold on a period-to-period basis include the volume of products sold, mix of products sold, third-party quality costs, transportation, overhead allocations and changes in inventory provisions.

The components of cost of goods sold are as follows:


	Three Months Ended March 31,					% (Decrease)
		2024			2023
Inventory expensed to cost of goods sold			3,382			5,209		(35.1)	%
Inventory provision, net			96			193		(50.3)	%
Other production costs			568			792		(28.3)	%
Service costs			311			—		100.0	%
Depreciation and amortization			856			899		(4.8)	%
Cost of goods sold			$	5,213		$	7,093	(26.5)	%

Cost of goods sold decreased 26.5% for the three months ended March 31, 2024 compared to the three months ended March 31, 2023, primarily due to lower unit sales volume and a decrease in variable operating costs. The decrease was partially offset by an increase in services costs related to the DeFloria service agreement.

Depreciation and amortization expense for the three months ended March 31, 2024 and March 31, 2023 was $2,493 and $3,792, respectively, of which $856 and $899, respectively, was expensed to cost of goods sold. The remaining depreciation and amortization expenses of $1,637 and $2,893, respectively, was expensed to Selling, general, and administrative expenses.

Gross Profit

The primary factors that can impact gross profit margins include the volume of products sold, revenue mix between DTC e-commerce and B2B, product sales mix, promotional and sales discount rate, manufacturing spend, transportation costs, and changes in inventory provisions.

Gross profit and gross profit margin are as follows:


	Three Months Ended March 31,						% (Decrease)
		2024				2023
Gross profit			$	6,911			$	9,917		(30.3)	%
Gross margin			57.0		%		58.3		%	(2.2)	%

Gross profit decreased 30.3% for the three months ended March 31, 2024 compared to the three months ended March 31, 2023. The decrease is primarily related to lower net revenue in both the DTC and B2B channels as well was lower variable operating costs.

Selling, General, and Administrative Expenses

Total Selling, general, and administrative expenses are as follows:


	Three Months Ended March 31,					% (Decrease)
		2024			2023
Selling, general, and administrative expenses			$	15,280		$	17,513	(12.8)	%

Total Selling, general, and administrative expenses for the three months ended March 31, 2024 and March 31, 2023 were $15,280 and $17,513, respectively. The 12.8% decrease was primarily attributable to $1 million in cost saving measures within e-commerce and marketing compared to the to the three months ended March 31, 2023. Additionally, the amended MLB Promotional Rights Agreement resulted in a decrease in amortization expense related to MLB assets of approximately $850 compared the prior period. To better align expenses to current revenue levels, the Company has taken actions to significantly reduce expenses company-wide in 2024 by approximately $15 million year-over-year, mainly through operating efficiency improvements, and stringent cost controls.

Depreciation and amortization expensed to Selling, general, and administrative expenses for the three months ended March 31, 2024 and March 31, 2023 were $1,637 and $2,893, respectively.

Total research and development expenses expensed to Selling, general, and administrative expense for the three months ended March 31, 2024 and March 31, 2023 were $751 and $546, respectively. Research and development expenses primarily include personnel costs related to our R&D science division as well as R&D related projects advancing Hemp cannabinoid science through research programs that provide a better understanding of the therapeutic uses of cannabinoids.

Total Change in Fair Value of Financial Instruments

Total change in fair value of financial instruments is as follows:


	Three Months Ended March 31,				% (Decrease)
	2024		2023
Change in fair value of financial instruments	$	(1,860)	$	5,382	(134.6)	%

Total change in fair value of financial instruments for the three months ended March 31, 2024 and March 31, 2023 was loss of $1,860 and gain of $5,382, respectively. For the three months ending March 31, 2024, the decrease in the change in fair value of financial instruments was due to a loss of $951 in the fair value of the SBH Purchase Option compared to a loss of $300 as of March 31, 2023. The fair value of the SBH Purchase Option is revalued at each reporting date with changes primarily based on financial projections of Stanley Brothers USA and the probability and timing of exercise.

Additionally, the decrease was also partially attributable to the revaluation of the fair value of the investment in DeFloria resulting in a loss of $800. The decrease in value for DeFloria was a result of the issuance of convertible debt during the period. The investment in DeFloria was entered into in April 2023 and as such there was no fair value for the three months ended March 31, 2023.

Finally, the loss for the three months ended March 31, 2024 was also caused by a net loss $109 from the revaluation of the debt conversion option and debt interest rate conversion feature. For the three months ended March 31, 2023, the Company recognized a net gain of $5,652 related to the revaluation of these instruments.

Liquidity and Capital Resources

As of March 31, 2024 and December 31, 2023, the Company had total current liabilities of $19,632 and $23,646, respectively, and cash and cash equivalents of $38,510 and $47,820, respectively, to meet its current obligations.

The Company expects a reduction in overall selling, general, and administrative expenses in 2024 as a result of several actions taken in the first quarter of 2024. This includes improvements in operating efficiency throughout the business, cost savings from a more efficient e-commerce platform and associated information technology upgrades, and a data-driven reorganization of its B2B business and retail partnering strategies. Additionally, costs associated with the Company’s MLB partnership and associated Promotional Rights Agreement will be approximately $3 million lower in 2024.

The Company's primary sources of liquidity are its net cash on hand from operations and sales of its securities from time to time. The Company's ability to fund its operations for the next twelve months and thereafter will depend on its future operating performance, particularly revenue growth, which can be affected by general economic conditions, industry regulatory changes, and other factors beyond the Company's control. We believe that our existing cash and cash equivalents, and short-term investments will provide sufficient liquidity to fund operations and planned capital expenditures for the next 12 months.

In addition to cash provided by operations, the Company may fund long-term liquidity requirements through various sources of capital. The Company regularly considers fundraising opportunities and may decide, from time to time, to raise capital through borrowings or issuances of additional equity and/or debt securities. The Company’s ability to raise funds through the issuance of additional equity and/or debt securities is dependent on a number of factors, including the current state of the capital markets, investor sentiment, and intended use of proceeds.

Cash Flows

Cash from Operating Activities

Net cash used in operating activities for the three months ended March 31, 2024 and March 31, 2023 were as follows:


	Three Months Ended March 31,
	2024		2023
Net cash used in operating activities	$	(7,179)	$	(6,073)

For the three months ended March 31, 2024, the increase in cash used in operations is primarily due to cash outflows of $2,500 associated with the MLB Promotional Rights Agreement, compared to $2,000 for the three months ended March 31, 2023.

Cash from Investing Activities

Net cash used in investing activities for the three months ended March 31, 2024 and March 31, 2023 were as follows:


	Three Months Ended March 31,
	2024		2023
Net cash used in investing activities	$	(2,033)	$	(40)

For the three months ended March 31, 2024, the increase in cash used in investing activities was driven primarily by machinery purchases as part of the Company's plan to in-source topical and gummy production.

Net cash provided by financing activities for the three months ended March 31, 2024 and March 31, 2023 were as follows:


	Three Months Ended March 31,
	2024		2023
Net cash used in financing activities	$	(98)	$	(69)

For the three months ended March 31, 2024 and March 31, 2023, the change was primarily due to the vesting of restricted stock units.

Off-Balance Sheet Arrangements

As of March 31, 2024 and December 31, 2023, we do not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on our results of operations or financial condition, including, and without limitation, such considerations as liquidity and capital resources.

Related party transactions

On April 6, 2023, the Company jointly formed an entity, DeFloria, with AJNA and BAT. AJNA is a botanical drug development company. AJNA is partially owned and was co-founded by a co-founder of Charlotte's Web. BAT holds an equity interest in the entity in the form of 200,000 preferred units following its $10 million investment and has the right to participate in future equity issuances to maintain its pro rata equity position. The Company and AJNA each hold 400,000 of the entity's voting common units (Note 3). Effective May 1, 2023, the Company entered into an 8% interest bearing note receivable with DeFloria for the sale of lab equipment in the amount of $170. The principal and interest of the note receivable will be paid in 36 monthly installments. As of March 31, 2024, the remaining note receivable of $113 is presented in other assets in the condensed consolidated balance sheets. On February 12, 2024, BAT invested an additional $3 million in DeFloria in the form of convertible debt. Additionally on February 12, 2024, the Company and DeFloria entered into a separate master services agreement in which the Company will be compensated for the provision of certain services to DeFloria. For the three months ended March 31, 2024, the Company recognized $311 in revenue and cost of goods sold, respectively, related to the service agreement with DeFloria. Additionally, the Company has an accounts receivable balance due from DeFloria of $74 for the three months ended March 31, 2024.

Recently Adopted Accounting Principles

There are no new accounting pronouncements adopted by the FASB that had or may have a material impact on the accompanying consolidated financial statements.

Critical Accounting Policies and Estimates

Listed below are the accounting policies and estimates we believe are critical to our financial statements due to the degree of uncertainty regarding the estimates or assumptions involved and the magnitude of the asset, liability, revenue or expense being reported. Please also refer to Note 2 of our notes to condensed consolidated financial statements for a discussion on recently adopted and issued accounting pronouncements.

Fair Value Option

The Company has elected the fair value option in accordance with ASC 825-10 guidance to record its SBH Purchase Option. Under ASC 825-10, a business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date. The SBH Purchase Option is classified as a financial asset in the condensed consolidated balance sheets and is remeasured at fair value at each reporting date, with changes to fair value recognized in the condensed consolidated statements of operations for the period. The use of assumptions for the fair value determination includes a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. The Monte Carlo valuation model considers multiple revenue and EBITDA outcomes for Stanley Brothers USA and other probabilities in assigning a fair value. Primary assumptions utilized include financial projections of Stanley Brothers USA and the probability and timing of exercise asserted by the Company.

Investment in Unconsolidated Entities

The Company has a variable interest in the investment in DeFloria; however, the Company is not the primary beneficiary of DeFloria as it lacks the power to direct DeFloria's key activities. The Company concluded that the investment in DeFloria should not be consolidated. In accordance with ASC 825-10, equity method investments are eligible for the fair value option as they represent recognized financial assets. As the Company was not required to consolidate the investment and does not meet any of the other scope exceptions, the Company had the ability to adopt the fair value option for the investment at inception. The investment was remeasured at fair value after each reporting date, with changes recognized in condensed consolidated statements of operations, as changes in fair value of financial instruments for the period.

The use of assumptions for the fair value determination of the investment in Defloria included a high degree of subjectivity and judgment using unobservable inputs (level 3 on the fair value hierarchy), which results in estimation uncertainty. To determine the value of the investment, the Company utilizes an Option Pricing Model (OPM). The OPM considers the various terms of the stockholder agreements, including the level of seniority among the securities, dividend policy, conversion ratios, and cash allocations upon liquidation of the entity. The OPM is appropriate when the range of potential future outcomes is difficult to predict with any certainty.

Inventories

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less any applicable selling expenses. Cost includes all expenses for direct raw materials inputs, as well as costs directly attributable to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity. Cost is determined by use of the weighted average method. To determine if a provision for inventories is required, the Company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions, including forecasted demand compared to quantities on hand, as well as other factors such as potential excess or aged inventories based on product shelf life, and other factors that affect inventory obsolescence. The Company's inventories of harvested hemp are recorded at cost to grow and harvest. Raw materials costs as well as production costs are included in the carrying value of the Company's finished goods inventory. The Company's inventory production process for cannabinoid products includes cultivating botanical raw material. Because of the duration of the cultivation process, a portion of the inventory will not be sold within one year. Consistent with the practice in other industries that cultivate botanical raw materials, all inventory is classified as a current asset.

Impairment of Long-Lived Assets

The Company reviews intangible assets with indefinite useful lives for impairment at least annually and reviews all intangible assets for impairment whenever events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. Long-lived assets, such as property and equipment and intangible assets subject to depreciation and amortization, as well as indefinite lived intangibles and goodwill are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable or that the useful life is shorter than the Company had originally estimated. Recoverability of these assets is measured by comparison of the carrying amount of each asset or asset group to the future undiscounted cash flows the asset or asset group is expected to generate over their remaining lives. If the asset or asset group is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset or asset group. If the useful life is shorter than originally estimated, the Company amortizes the remaining carrying value over the new shorter useful life. Impairment losses are

recorded in selling, general, and administrative expense in the condensed consolidated statements of operations. There were no impairment losses recognized for the three months ended March 31, 2024 and 2023, respectively.

Convertible Debenture

The Company determined that the debenture is a freestanding financial instrument, which includes embedded derivatives. The embedded derivatives have been bifurcated from the debenture and accounted for separately in accordance with the provisions of ASC 815, Derivatives and Hedging. The Company reviewed the terms of the debenture and identified two material embedded features which required bifurcation and separate accounting pursuant to the provisions of ASC 815: 1) the interest rate conversion feature based on changes in federal regulations, and 2) the debt conversion option to common shares. The debt interest rate conversion feature is classified as a derivative asset and measured at fair value using a probability weighted income approach. The debt conversion option is classified as a derivative liability and measured at fair value using a Black-Scholes option pricing model. The Company allocated proceeds first to the derivatives measured at fair value and the residual amount was allocated to the debenture. Debt issuance costs are allocated to the debenture. The debt issuance costs are presented as a direct reduction from the face value of the debenture and amortized over the stated term of the debenture.

Income Taxes

The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets or liabilities are computed based on the temporary difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal income tax rate in effect for the year in which the differences are expected to reverse. Deferred income tax expense or benefit is based on the changes in the deferred income tax assets or liabilities from period to period. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized.

Significant judgment is required in determining the Company's provision for income taxes, deferred tax assets and liabilities and the valuation allowance recorded against net deferred tax assets. The Company assesses the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence. Factors reviewed include projections of pre-tax book income for the foreseeable future, determination of cumulative pre-tax book income or loss, earnings history, and forecasting reliability. It is the Company's policy to offset indefinite lived deferred tax assets with indefinite lived deferred tax liabilities. The Company provided a full valuation allowance on deferred tax assets because it is more likely than not that deferred tax assets will not be realized.

The Company accounts for uncertainties in income taxes under ASC Topic 740, which prescribes a recognition threshold and measurement methodology to recognize and measure an income tax position taken, or expected to be taken, in a tax return. With respect to any tax positions that do not meet the recognition threshold, a corresponding liability, including interest and penalties, is recorded in the condensed consolidated financial statements. The Company may be subject to examination by tax authorities where the Company conducts operations. The earliest income tax year that may be subject to examination is 2019. The Company has recorded an uncertain tax position as of March 31, 2024 and December 31, 2023. The Company's policy is to recognize interest and penalties on taxes, if any, within the statement of operations as income tax expense.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customer ("ASC 606"). The Company elected to early adopt ASC 606 as of January 1, 2018, as permitted by the standard. The Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to arrangements that meet the definition of a contract under the standard, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of revenue accounting, the Company evaluates the goods or services promised within each contract related performance obligation and assesses whether each promised good or service is distinct. The Company recognizes as revenue, the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company recognizes revenue from customers when control of the goods or services is transferred to the customer, generally when products are shipped, at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Freight revenue is included in revenue on the condensed consolidated statements of operations, and is generally exempt from state sales taxes. Sales tax collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from revenue in the condensed consolidated statements of operations. Contracts are written to include standard discounts and allowances. Contracts are not written to include advertising allowances, tiered discounts or any other performance obligation. Since the Company's contracts involve the delivery of various tangible products, the arrangements are considered to contain only a single performance obligation, as such there is no allocation of the transaction price. The Company also offers e-commerce discounts and promotions through its online rewards program. The Charlotte's Web Loyalty Program offers customers rewards points for every dollar spent through the Company website to earn store credit for future purchases. The Company defers recognition of revenue for unredeemed awards until the following occurs: (1) rewards are redeemed by the consumer, (2) points or certificates expire, or (3) an estimate of the expected unused portion of points or certificates is applied, which is based on historical redemption patterns.

Any product that does not meet the customer's expectations can be returned within the first 30 days of delivery in exchange for another product or for a full refund. Generally, any product sold through a distributor or retailer must be returned to the original purchase location for any return or exchange. The Company accounts for customer returns utilizing the "expected value method". Expected amounts are excluded from revenue and recorded as a "refund liability" that represents the Company's obligation to return the customer's consideration. Estimates are based on actual historical and current specific data.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The information under this item is not required to be provided by smaller reporting companies.

Item 4. Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of March 31, 2024, our disclosure controls and procedures were effective to ensure the timely disclosure of required information in our SEC filings.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company's internal control over financial reporting during the quarter ending March 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II

Item 1. Legal Proceedings

From time to time, the Company may be involved in various regulatory issues, claims and lawsuits arising in the ordinary course of business, none of which, in the opinion of management, is expected to have a material adverse effect on the Company's results of operations or financial condition.

At present, the Company is not a party to any material pending legal proceedings, other than ordinary routine litigation incidental to the business. Nor is the Company or its property the subject of any legal proceedings, known or contemplated, that involve a claim for damages exclusive of interest and costs that meet or exceed 10% of its current assets.

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the year ended December 31, 2023 includes a detailed discussion of our risk factors under the heading "Part I, Item 1A—Risk Factors". Except as set forth below, there have been no material changes from such risk factors during the quarter ended March 31, 2024. You should consider carefully the risk factors set forth in this Form 10-Q and discussed in our Annual Report on Form 10-K for the year ended December 31, 2023 and all other information contained in or incorporated by reference in this Form 10-Q before making an investment decision. If any of the risks discussed herein or in the Annual Report on Form 10-K for the year ended December 31, 2023 actually occur, they may materially harm our business, financial condition, operating results, cash flows or growth prospects. As a result, the market price of our common shares could decline, and you could lose all or part of your investment. Additional risks and uncertainties that are not yet identified or that we think are immaterial may also materially harm our business, financial condition, operating results, cash flows or growth prospects and could result in a complete loss of your investment.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During the three months ended March 31, 2024, none of the Company's directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).

Item 6. Exhibits

Documents filed as part of this report.

Exhibit No.

Description

Location

10.1†

Amendment No. 1 to Charlotte's Web Holdings, Inc. Amended 2018 Long-Term Incentive Plan dated April 29, 2021.

Exhibit 10.18.1 to the Annual Report on Form 10-K (File No. 000-56364) filed with the SEC on March 21, 2024 is incorporated herein by reference.

10.2†

Letter dated as of March 19, 2024 to Jessica Saxton re: Amendment to Offer of Employment with Charlotte’s Web Holdings, Inc.

Exhibit 10.28.1 to the Annual Report on Form 10-K (File No. 000-56364) filed with the SEC on March 21, 2024 is incorporated herein by reference.

10.3+

First Amendment to Promotional Rights Agreement, executed February 5, 2024, by and among MLB Advanced Media L.P., on its own behalf and on behalf of Major League Baseball Properties, Inc., the Office of the Commissioner of Baseball, The MLB Network, LLC and the Major League Baseball Clubs and Charlotte’s Web Holdings, Inc.

Exhibit 10.32.1 to the Annual Report on Form 10-K (File No. 000-56364) filed with the SEC on March 21, 2024 is incorporated herein by reference.

31.1

Certification of Periodic Report by Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

Filed herewith

31.2

Certification of Periodic Report by Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

Filed herewith

32.1

Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Filed herewith

32.2

Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Filed herewith

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

Filed herewith

101.SCH

Inline XBRL Taxonomy Extension Schema Document

Filed herewith

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

Filed herewith

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

Filed herewith

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

Filed herewith

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Filed herewith

† Indicates a management contract or compensatory plan or arrangement.

∔ Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) and/or Item 601(b)(10)(iv) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		CHARLOTTE'S WEB HOLDINGS, INC.

May 8, 2024	By:	/s/ Jessica Saxton
(Date)		Jessica Saxton
		(Chief Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

Signatures

Title

Date

/s/ William Morachnick

Chief Executive Officer (Principal Executive Officer)

May 8, 2024

William Morachnick

/s/ Jessica Saxton

Chief Financial Officer (Principal Financial Officer)

May 8, 2024

Jessica Saxton

/s/ Sarah Cambridge

Chief Accounting Officer (Principal Accounting Officer)

May 8, 2024

Sarah Cambridge

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A‑14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002

I, William Morachnick, certify that:

1.I have reviewed this quarterly report on Form 10‑Q of Charlotte's Web Holdings, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2024


/s/ William Morachnick

William Morachnick

Chief Executive Officer

(Principal Executive Officer)

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13A‑14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002

I, Jessica Saxton, certify that:

1.I have reviewed this quarterly report on Form 10‑Q of Charlotte's Web Holdings, Inc.;

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2024


/s/ Jessica Saxton

Jessica Saxton

Chief Financial Officer

(Principal Financial Officer)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Charlotte's Web Holdings, Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission (the "Report"), I, William Morachnick, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Dated: May 8, 2024


/s/ William Morachnick

William Morachnick

Chief Executive Officer

(Principal Executive Officer)

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Charlotte's Web Holdings, Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission (the "Report"), I, Jessica Saxton, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

Dated: May 8, 2024


/s/ Jessica Saxton

Jessica Saxton

Chief Financial Officer

(Principal Financial Officer)

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2024	May 06, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	000-56364
Entity Registrant Name	Charlotte's Web Holdings, Inc.
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	98-1508633
Entity Address, Address Line One	700 Tech Court
Entity Address, City or Town	Louisville
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80027
City Area Code	720
Local Phone Number	484-8930
Title of 12(g) Security	Common stock, no par value
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		157,227,855
Amendment Flag	false
Entity Central Index Key	0001750155
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 38,510	$ 47,820
Accounts receivable, net	1,725	1,950
Inventories, net	22,487	21,538
Prepaid expenses and other current assets	5,535	6,864
Total current assets	68,257	78,172
Property and equipment, net	28,255	27,513
License and media rights	17,614	17,070
Operating lease right-of-use assets, net	14,206	14,601
Investment in unconsolidated entity	10,200	11,000
SBH purchase option and other derivative assets	1,579	2,602
Intangible assets, net	1,051	887
Other long-term assets	616	703
Total assets	141,778	152,548
Current liabilities:
Accounts payable	3,991	2,860
Accrued and other current liabilities	8,230	8,682
Lease obligations – current	2,339	2,252
License and media rights payable - current	5,072	9,852
Total current liabilities	19,632	23,646
Convertible debenture	42,736	42,528
Lease obligations	15,063	15,655
License and media rights payable	13,899	11,338
Derivative and other long-term liabilities	3,780	3,823
Total liabilities	95,110	96,990
Commitments and contingencies (Note 7)
Shareholders’ equity:
Common shares, nil par value; unlimited shares authorized; 157,227,855 and 154,332,366 shares issued and outstanding as of March 31, 2024 and December 31, 2023	1	1
Additional paid-in capital	328,024	327,280
Accumulated deficit	(281,357)	(271,723)
Total shareholders’ equity	46,668	55,558
Total liabilities and shareholders’ equity	$ 141,778	$ 152,548

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common shares, issued (in shares)	157,227,855	154,332,366
Common shares, outstanding (in shares)	157,227,855	154,332,366

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 12,124	$ 17,010
Cost of goods sold	5,213	7,093
Gross profit	6,911	9,917
Selling, general, and administrative expenses	15,280	17,513
Operating loss	(8,369)	(7,596)
Change in fair value of financial instruments	(1,860)	5,382
Other income (expense), net	611	(698)
Loss before provision for income taxes	(9,618)	(2,912)
Income tax expense	(16)	0
Net loss	$ (9,634)	$ (2,912)
Per common share amounts (Note 10)
Net loss per common share, basic (in usd per share)	$ (0.06)	$ (0.02)
Net loss per common share, diluted (in usd per share)	$ (0.06)	$ (0.02)

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Shares	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022		152,135,026
Beginning balance at Dec. 31, 2022	$ 77,505	$ 1	$ 325,431	$ (247,927)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued upon vesting of restricted share units, net of withholding (in shares)		297,888
Common shares issued upon vesting of restricted share units, net of withholding	(69)		(69)
Share-based compensation	375		375
Net loss	(2,912)			(2,912)
Ending balance (in shares) at Mar. 31, 2023		152,432,914
Ending balance at Mar. 31, 2023	74,899	$ 1	325,737	(250,839)
Beginning balance (in shares) at Dec. 31, 2023		154,332,366
Beginning balance at Dec. 31, 2023	55,558	$ 1	327,280	(271,723)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued upon vesting of restricted share units, net of withholding (in shares)		2,895,489
Common shares issued upon vesting of restricted share units, net of withholding	(98)		(98)
Share-based compensation	842		842
Net loss	(9,634)			(9,634)
Ending balance (in shares) at Mar. 31, 2024		157,227,855
Ending balance at Mar. 31, 2024	$ 46,668	$ 1	$ 328,024	$ (281,357)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (9,634)	$ (2,912)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,493	3,792
Change in fair value of financial instruments	1,860	(5,351)
Convertible debenture and other accrued interest	1,015	697
Share-based compensation	842	375
Changes in right-of-use assets	443	493
Other	(956)	768
Changes in operating assets and liabilities:
Accounts receivable, net	98	(1,212)
Inventories, net	(1,026)	1,187
Prepaid expenses and other current assets	150	480
License and media rights	(2,500)	(2,000)
Operating lease obligations	(551)	(925)
Accounts payable, accrued and other liabilities	663	(1,098)
Other operating assets and liabilities, net	(76)	(367)
Net cash used in operating activities	(7,179)	(6,073)
Cash flows from investing activities:
Purchases of property and equipment and intangible assets	(2,060)	(70)
Proceeds from sale of assets	27	30
Net cash used in investing activities	(2,033)	(40)
Cash flows from financing activities:
Other financing activities	(98)	(69)
Net cash used in financing activities	(98)	(69)
Net decrease in cash and cash equivalents	(9,310)	(6,182)
Cash and cash equivalents —beginning of period	47,820	66,963
Cash and cash equivalents —end of period	38,510	60,781
Non-cash activities:
Non-cash purchase of property and equipment and intangible assets	$ (374)	$ 0

DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS	DESCRIPTION OF BUSINESS AND PRESENTATION OF FINANCIAL STATEMENTS Description of the Business Charlotte's Web Holdings, Inc. together with its subsidiaries (collectively "Charlotte's Web" or the "Company") is a public company incorporated pursuant to the laws of the Province of British Columbia and is also a Certified B Corp. The Company's common shares are publicly listed on the Toronto Stock Exchange ("TSX") under the symbol "CWEB" and quoted on the OTCQX under the symbol "CWBHF." The Company's corporate headquarters is located in Louisville, Colorado in the United States of America. The majority of the Company's business is conducted in the United States of America. The Company's primary products are made from proprietary strains of whole-plant hemp extracts containing a full spectrum of phytocannabinoids, terpenes, flavonoids, and other hemp compounds. Hemp extracts are produced from the plant Cannabis sativa L. ("Cannabis"), and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol ("THC") concentration of not more than 0.3% on a dry weight basis ("Hemp"). The Company is engaged in research involving the effectiveness of a broad variety of compounds derived from Hemp. The Company does not currently produce or sell medical or recreational marijuana or products derived from high THC Cannabis plants. The Company does not currently have any plans to expand into such high THC products in the near future. The Company's product categories include full spectrum hemp extract oil tinctures (liquid product), gummies, capsules, CBD topical creams and lotions, and pet products. The Company's products are distributed through its e-commerce website, third-party e-commerce websites, select distributors, health practitioners, and a variety of brick-and-mortar specialty retailers. The Company grows its proprietary hemp domestically in the United States on farms leased in northeastern Colorado and sources hemp through contract farming operations in Arizona, Kentucky, Oregon, and Canada. The Hemp grown in Canada is utilized exclusively in the Canadian markets or for research purposes and not in products sold within the United States. In furtherance of the Company's research and development ("R&D") efforts, the Company established CW Labs, an internal division for R&D, to expand the Company's efforts around the science of hemp derived compounds. CW Labs is currently engaged in clinical trials addressing Hemp-based health solutions. CW Labs is located in Louisville, Colorado at the Company's current good manufacturing practice ("cGMP") production and distribution facility.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

Basis of Presentation

Inventories

Revenue Recognition


	Three Months Ended March 31,
	2024		2023
Direct-to-consumer	$	7,772	$	11,268
Business-to-business	4,041		5,742
Service revenue	311		—
Total revenue	$	12,124	$	17,010

Substantially all of the Company's revenue is earned in the United States.

Recently Adopted Accounting Pronouncements

There are no new accounting pronouncements adopted by the FASB that had or may have a material impact on the accompanying unaudited interim condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

FAIR VALUE MEASUREMENT

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENT


	March 31, 2024
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	779	$	779
Debt interest rate conversion feature	—		—		800		800
Total financial assets	$	—	$	—	$	1,579	$	1,579

Investment in unconsolidated entity:	$	—	$	—	$	10,200	$	10,200

Financial liabilities:
Debt conversion option	$	—	$	3,200	$	—	$	3,200


	December 31, 2023
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	1,730	$	1,730
Debt interest rate conversion feature	—		—		872		872
Total financial assets	$	—	$	—	$	2,602	$	2,602

Investment in unconsolidated entity:	$	—	$	—	$	11,000	$	11,000

Financial liabilities:
Debt conversion option	$	—	$	3,213	$	—	$	3,213

There were no transfers between levels of the hierarchy during the three months ended March 31, 2024, and the year ended December 31, 2023.

Investment in Unconsolidated Entity

The following additional assumptions are used in the model:


	March 31,	December 31,
	2024	2023
Expected term (years)	6.0	6.3
Volatility	75.0%	70.0%
Risk-free interest rate	4.2%	3.9%
Expected dividend yield	—%	—%
Discount for lack of marketability	20.0%	20.0%

Convertible Debt Derivatives

Debt Interest Rate Conversion Feature


	March 31,	December 31,
	2024	2023
Stated interest rate	5.0%	5.0%
Adjusted interest rate	1.5%	1.5%
Implied debt yield	12.8%	11.0%
Federal regulation probability	Various	Various
Year of event	Various	Various

Debt Conversion Option

The following table provides the assumption regarding Level 2 fair value measurements inputs at their measurement dates:


	March 31,	December 31,
	2024	2023
Expected volatility	87.9%	87.4%
Expected term (years)	5.6	5.9
Risk-free interest rate	4.2%	3.9%
Expected dividend yield	—%	—%
Value of underlying share	C$0.28	C$0.27
Exercise price	C$2.00	C$2.00

Stanley Brothers USA Holdings Purchase Option


	March 31,	December 31,
	2024	2023
Expected volatility	125.0%	125.0%
Expected term (years)	1.9	2.2
Risk-free interest rate	4.6%	4.2%
Weighted average cost of capital	50.9%	50.6%

INVENTORIES

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

INVENTORIES

Inventories consist of the following:


	March 31,		December 31,
	2024		2023
Harvested Hemp and seeds	$	8,736	$	9,300
Raw materials	10,637		9,726
Finished goods	6,668		6,320
	26,041		25,346
Less: inventory provision	(3,554)		(3,808)
Total	$	22,487	$	21,538

LICENSE AND MEDIA RIGHTS

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

LICENSE AND MEDIA RIGHTS

MLB Promotion Rights Agreement

The MLB First Amendment agreement extended the maturities of the future payment by an additional 2 years. Maturities of the MLB license and media rights payable as of March 31, 2024 are as follows:


2024 (9 months remaining)	$	2,500
2025	5,500
2026	6,000
2027	6,500
Total payments	$	20,500
Less: Imputed interest	(1,529)
Total license and media rights payable	$	18,971
Less: Current license liabilities	(5,072)
Total non-current license and media rights payable	$	13,899

As of March 31, 2024, expected amortization of licensed properties are as follows:


2024 (9 months remaining)	$	2,923
2025	3,897
2026	3,897
2027	3,897
Total future amortization	$	14,614

DEBT

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

DEBT

Convertible Debenture

The following is a summary of the Company's convertible debenture as of March 31, 2024:


	As of March 31, 2024
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	59,544	$	(16,808)	$	42,736

The following is a summary of the Company's convertible debenture as of December 31, 2023:


	As of December 31, 2023
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	60,116	$	(17,588)	$	42,528


	Three Months Ended March 31,
	2024		2023
Interest expense	$	733	$	697
Amortization of debt discounts and costs	401		319
Total interest and amortization expense	$	1,134	$	1,016

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Contingencies From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. Although the ultimate aggregate amount of monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, management believes that as of March 31, 2024 there is no litigation pending that could have, individually and in the aggregate, a material adverse effect on the Company’s financial position, results of operations or cash flows.

LEASES

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

LEASES

Maturities of operating lease liabilities as of March 31, 2024 are as follows:


	Operating Leases
2024 (9 months remaining)	$	2,449
2025	2,892
2026	2,169
2027	1,844
2028	1,762
Thereafter	11,884
Total lease obligation	23,000
Less: Imputed interest	(5,598)
Total lease liabilities	17,402
Less: Current lease liabilities	2,339
Total non-current lease liabilities	$	15,063

SHAREHOLDERS’ EQUITY	3 Months Ended
SHAREHOLDERS’ EQUITY	Mar. 31, 2024
Equity [Abstract]
SHAREHOLDERS’ EQUITY	SHAREHOLDERS’ EQUITY As of March 31, 2024 and December 31, 2023, the Company's share capital consists of one class of issued and outstanding shares: common shares. The Company is also authorized to issue preferred shares issuable in series. To date, no shares of preferred shares have been issued or are outstanding. Common Shares As of March 31, 2024 and December 31, 2023, the Company was authorized to issue an unlimited number of common shares, which have no par value.

LOSS PER SHARE

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

LOSS PER SHARE

The following table sets forth the computation of basic and dilutive net loss per share attributable to common shareholders:


	Three Months Ended March 31,
	2024		2023
Net loss	$	(9,634)	$	(2,912)
Weighted-average number of common shares - basic	156,036,670		152,314,150
Dilutive effect of stock options and awards	—		—
Weighted-average number of common shares - diluted	156,036,670		152,314,150
Loss per common share – basic and diluted	$	(0.06)	$	(0.02)


	March 31,
	2024	2023
Outstanding options	5,522,942	4,386,215
Outstanding restricted share units	3,750,000	2,216,022
Total	9,272,942	6,602,237

SHARE-BASED COMPENSATION

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

Stock options


	Three Months Ended March 31,
		2023
Expected volatility		89.5%
Expected term (years)		5.5-6.5
Risk-free interest rate		3.4%
Expected dividend yield		0%
Value of underlying share		$0.56


	Number of Options	Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contract Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	5,780,134	$	0.75	8.56	$	—
Granted	—	—
Exercised	—	—
Forfeited (and expired)	(257,192)	0.53
Outstanding as of March 31, 2024	5,522,942	$	0.77	8.31	$	—

Exercisable/vested as of March 31, 2024	2,761,000	$	1.06	7.39	$	—

There were no options granted during the three months ended March 31, 2024. The weighted average grant-date fair value of options granted during the three months ended March 31, 2023 was $0.56.

There were no options exercised during the three months ended March 31, 2024 and 2023.

Restricted share units

Details of the number of restricted share units outstanding under the 2018 Plan is as follows:


	Number of Shares	Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2023	7,250,766	$	0.31
Granted	—	$	—
Forfeited	(85,731)	$	0.53
Vested	(2,895,489)	$	0.30
Shares withheld upon vesting	(519,546)	$	0.53
Outstanding as of March 31, 2024	3,750,000	$	0.29

Share-based Compensation Expense

INCOME TAXES	3 Months Ended
INCOME TAXES	Mar. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company reported income tax expense of $16 and $0 for the three months ended March 31, 2024 and 2023, respectively. The Company's effective tax rate in the three months ended March 31, 2024 and 2023 was (0.2)% and 0%, respectively. The Company's effective tax rates differ from the U.S. federal statutory rate of 21.0% for the three months end March 31, 2024 and 2023, respectively, primarily due to the valuation allowance. The effective tax rate for the three months ended March 31, 2024 is consistent with the three months ended March 31, 2023, as the Company has been in a full valuation allowance for both periods.

RELATED PARTY TRANSACTIONS	3 Months Ended
RELATED PARTY TRANSACTIONS	Mar. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Effective November 2020, the Company issued a secured promissory note, where $1,000 was loaned to one of the Company's founders. The note receivable was secured by equity instruments with certain founders of the Company, bore interest at 3.25% per annum, and required the unpaid principal and unpaid interest balances to be paid on or before the maturity date of November 13, 2021. Effective December 28, 2023, the Company entered into a second amendment of the promissory note to extend the maturity date until November 13, 2024. According to the terms of the agreement, no additional interest will accrue through the payment date. The note has been fully reserved for as of December 31, 2023. On March 2, 2021, the Company entered into the SBH Purchase Option with Stanley Brothers USA as discussed above (Note 3 "Fair Value Measurement"). The SBH Purchase Option was purchased for total consideration of $8,000. Certain founders of the Company, who are or were employees at the time, are the majority shareholders of Stanley Brothers USA. On April 6, 2023, the Company jointly formed an entity, DeFloria, with AJNA and BAT. AJNA is a botanical drug development company. AJNA is partially owned and was co-founded by a co-founder of Charlotte's Web. BAT holds an equity interest in the entity in the form of 200,000 preferred units following its $10 million investment and has the right to participate in future equity issuances to maintain its pro rata equity position. The Company and AJNA each hold 400,000 of the entity's voting common units (Note 3). Effective May 1, 2023, the Company entered into an 8% interest bearing note receivable with DeFloria for the sale of lab equipment in the amount of $170. The principal and interest of the note receivable will be paid in 36 monthly installments. As of March 31, 2024, the remaining note receivable of $113 is presented in other assets in the condensed consolidated balance sheets. On February 12, 2024, BAT invested an additional $3 million in DeFloria in the form of convertible debt (refer to Note 3). Additionally on February 12, 2024, the Company and DeFloria entered into a separate master services agreement pursuant to which the Company will be compensated for the provision of certain services to DeFloria. For the three months ended March 31, 2024, the Company recognized $311 in revenue and cost of goods sold, respectively, related to the service agreement with DeFloria. Additionally, the Company has an accounts receivable balance due from DeFloria of $74 for the three months ended March 31, 2024.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net loss	$ (9,634)	$ (2,912)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Basis of Presentation

Inventories

Revenue Recognition


	Three Months Ended March 31,
	2024		2023
Direct-to-consumer	$	7,772	$	11,268
Business-to-business	4,041		5,742
Service revenue	311		—
Total revenue	$	12,124	$	17,010

Substantially all of the Company's revenue is earned in the United States.

Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

There are no new accounting pronouncements adopted by the FASB that had or may have a material impact on the accompanying unaudited interim condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Schedule of Disaggregation of Revenue

The following table sets forth the disaggregation of the Company's revenue:


	Three Months Ended March 31,
	2024		2023
Direct-to-consumer	$	7,772	$	11,268
Business-to-business	4,041		5,742
Service revenue	311		—
Total revenue	$	12,124	$	17,010

FAIR VALUE MEASUREMENT (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis


	March 31, 2024
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	779	$	779
Debt interest rate conversion feature	—		—		800		800
Total financial assets	$	—	$	—	$	1,579	$	1,579

Investment in unconsolidated entity:	$	—	$	—	$	10,200	$	10,200

Financial liabilities:
Debt conversion option	$	—	$	3,200	$	—	$	3,200


	December 31, 2023
	Level 1		Level 2		Level 3		Total
Financial assets:
Stanley Brothers USA Holdings purchase option	$	—	$	—	$	1,730	$	1,730
Debt interest rate conversion feature	—		—		872		872
Total financial assets	$	—	$	—	$	2,602	$	2,602

Investment in unconsolidated entity:	$	—	$	—	$	11,000	$	11,000

Financial liabilities:
Debt conversion option	$	—	$	3,213	$	—	$	3,213

Schedule of Measurement inputs

The following additional assumptions are used in the model:


	March 31,	December 31,
	2024	2023
Expected term (years)	6.0	6.3
Volatility	75.0%	70.0%
Risk-free interest rate	4.2%	3.9%
Expected dividend yield	—%	—%
Discount for lack of marketability	20.0%	20.0%

The following additional assumptions are used in the model:


	March 31,	December 31,
	2024	2023
Stated interest rate	5.0%	5.0%
Adjusted interest rate	1.5%	1.5%
Implied debt yield	12.8%	11.0%
Federal regulation probability	Various	Various
Year of event	Various	Various

The following table provides the assumption regarding Level 2 fair value measurements inputs at their measurement dates:


	March 31,	December 31,
	2024	2023
Expected volatility	87.9%	87.4%
Expected term (years)	5.6	5.9
Risk-free interest rate	4.2%	3.9%
Expected dividend yield	—%	—%
Value of underlying share	C$0.28	C$0.27
Exercise price	C$2.00	C$2.00

The following additional assumptions are used in the model of the SBH Purchase Option:


	March 31,	December 31,
	2024	2023
Expected volatility	125.0%	125.0%
Expected term (years)	1.9	2.2
Risk-free interest rate	4.6%	4.2%
Weighted average cost of capital	50.9%	50.6%

INVENTORIES (Tables)

3 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:


	March 31,		December 31,
	2024		2023
Harvested Hemp and seeds	$	8,736	$	9,300
Raw materials	10,637		9,726
Finished goods	6,668		6,320
	26,041		25,346
Less: inventory provision	(3,554)		(3,808)
Total	$	22,487	$	21,538

LICENSE AND MEDIA RIGHTS (Tables)

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Schedule of License Liability Maturity

Maturities of the MLB license and media rights payable as of March 31, 2024 are as follows:


2024 (9 months remaining)	$	2,500
2025	5,500
2026	6,000
2027	6,500
Total payments	$	20,500
Less: Imputed interest	(1,529)
Total license and media rights payable	$	18,971
Less: Current license liabilities	(5,072)
Total non-current license and media rights payable	$	13,899

Schedule of Expected Amortization of Licensed Properties

As of March 31, 2024, expected amortization of licensed properties are as follows:


2024 (9 months remaining)	$	2,923
2025	3,897
2026	3,897
2027	3,897
Total future amortization	$	14,614

DEBT (Tables)

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Schedule of Convertible Debenture

The following is a summary of the Company's convertible debenture as of March 31, 2024:


	As of March 31, 2024
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	59,544	$	(16,808)	$	42,736

The following is a summary of the Company's convertible debenture as of December 31, 2023:


	As of December 31, 2023
	Principal Amount		Unamortized Debt Discount and Costs		Net Carrying Amount
Convertible Debenture
Convertible debenture due November 2029	$	60,116	$	(17,588)	$	42,528

Schedule of Interest Expense

The following is a summary of the interest expense and amortization expense, recorded within the condensed consolidated statements of operation, of the Company's convertible debenture for the three months ended March 31, 2024:


	Three Months Ended March 31,
	2024		2023
Interest expense	$	733	$	697
Amortization of debt discounts and costs	401		319
Total interest and amortization expense	$	1,134	$	1,016

LEASES (Tables)

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Schedule of Maturities of Operating Lease Liabilities

Maturities of operating lease liabilities as of March 31, 2024 are as follows:


	Operating Leases
2024 (9 months remaining)	$	2,449
2025	2,892
2026	2,169
2027	1,844
2028	1,762
Thereafter	11,884
Total lease obligation	23,000
Less: Imputed interest	(5,598)
Total lease liabilities	17,402
Less: Current lease liabilities	2,339
Total non-current lease liabilities	$	15,063

LOSS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of basic and dilutive net loss per share attributable to common shareholders:


	Three Months Ended March 31,
	2024		2023
Net loss	$	(9,634)	$	(2,912)
Weighted-average number of common shares - basic	156,036,670		152,314,150
Dilutive effect of stock options and awards	—		—
Weighted-average number of common shares - diluted	156,036,670		152,314,150
Loss per common share – basic and diluted	$	(0.06)	$	(0.02)

Schedule of Potentially Dilutive Awards

The potentially dilutive awards outstanding for each period are presented in the table below:


	March 31,
	2024	2023
Outstanding options	5,522,942	4,386,215
Outstanding restricted share units	3,750,000	2,216,022
Total	9,272,942	6,602,237

SHARE-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Inputs used in Valuation of Awards

The following principal inputs were used in the valuation of awards issued for the three months ended March 31, 2023:


	Three Months Ended March 31,
		2023
Expected volatility		89.5%
Expected term (years)		5.5-6.5
Risk-free interest rate		3.4%
Expected dividend yield		0%
Value of underlying share		$0.56

Schedule of Detail of the Number of Stock Options Outstanding


	Number of Options	Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contract Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	5,780,134	$	0.75	8.56	$	—
Granted	—	—
Exercised	—	—
Forfeited (and expired)	(257,192)	0.53
Outstanding as of March 31, 2024	5,522,942	$	0.77	8.31	$	—

Exercisable/vested as of March 31, 2024	2,761,000	$	1.06	7.39	$	—

Schedule of Details of the Number of Restricted Share Awards Outstanding

Details of the number of restricted share units outstanding under the 2018 Plan is as follows:


	Number of Shares	Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2023	7,250,766	$	0.31
Granted	—	$	—
Forfeited	(85,731)	$	0.53
Vested	(2,895,489)	$	0.30
Shares withheld upon vesting	(519,546)	$	0.53
Outstanding as of March 31, 2024	3,750,000	$	0.29

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 12,124	$ 17,010
Direct-to-consumer
Disaggregation of Revenue [Line Items]
Total revenue	7,772	11,268
Business-to-business
Disaggregation of Revenue [Line Items]
Total revenue	4,041	5,742
Service revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 311	$ 0

FAIR VALUE MEASUREMENT - Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Financial assets:
Stanley Brothers USA Holdings purchase option	$ 779	$ 1,730
Debt interest rate conversion feature	800	872
Total financial assets	1,579	2,602
Investment in unconsolidated entity	10,200	11,000
Financial liabilities:
Debt conversion option	3,200	3,213
Level 1
Financial assets:
Stanley Brothers USA Holdings purchase option	0	0
Debt interest rate conversion feature	0	0
Total financial assets	0	0
Investment in unconsolidated entity	0	0
Financial liabilities:
Debt conversion option	0	0
Level 2
Financial assets:
Stanley Brothers USA Holdings purchase option	0	0
Debt interest rate conversion feature	0	0
Total financial assets	0	0
Investment in unconsolidated entity	0	0
Financial liabilities:
Debt conversion option	3,200	3,213
Level 3
Financial assets:
Stanley Brothers USA Holdings purchase option	779	1,730
Debt interest rate conversion feature	800	872
Total financial assets	1,579	2,602
Investment in unconsolidated entity	10,200	11,000
Financial liabilities:
Debt conversion option	$ 0	$ 0

FAIR VALUE MEASUREMENT - Narrative (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Millions			3 Months Ended		12 Months Ended
	Feb. 12, 2024 USD ($)	Mar. 02, 2021 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2024 $ / shares	Dec. 31, 2023 USD ($)	Apr. 06, 2023 USD ($) $ / shares shares	Nov. 14, 2022 USD ($)	Nov. 14, 2022 CAD ($) $ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of financial instruments			$ (1,860)	$ 5,382
Investment in unconsolidated entity			10,200				$ 11,000
Debt interest rate conversion feature			$ 800				$ 872
Derivative Asset, Statement of Financial Position [Extensible Enumeration]			SBH purchase option and other derivative assets				SBH purchase option and other derivative assets
Debt conversion option			$ 3,200				$ 3,213
Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]			Derivative and other long-term liabilities
Purchase option		$ 8,000			$ 8,000
Purchase option, term					5 years
Purchase option, extension term					2 years
Warrant, percentage of outstanding shares					10.00%
Warrants expiration period					60 days
Gain (loss) on change in fair value of purchase option			$ (951)	(300)
Stanley Brothers USA Holdings purchase option			779				1,730
Debt Conversion Option
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (loss) related to debt conversion			(56)	6,257
Debt conversion option			3,200				3,213
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment in unconsolidated entity			10,200				11,000
Debt interest rate conversion feature			800				872
Debt conversion option			0				0
Stanley Brothers USA Holdings purchase option			779				1,730
Debt Interest Rate Conversion Feature
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (loss) related to debt conversion			(54)	$ (605)
BAT Group
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, convertible, ownership percentage of shares									19.90%	19.90%
Debt instrument, convertible, conversion price \| $ / shares										$ 2.00
BAT Group \| Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, annual increase, accrued interest									5.00%	5.00%
BAT Group \| Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, annual increase, accrued interest									1.50%	1.50%
BAT Group \| Convertible Notes Payable
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Principal Amount			$ 59,544				60,116		$ 56,800	$ 75.3
Debt instrument, convertible, ownership percentage of shares			19.90%
Debt instrument, convertible, conversion price \| $ / shares						$ 2.00
DeFloria
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity method ownership percentage								50.00%
British American Tobacco \| DeFloria
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Preferred units ownership percentage								100.00%
AJNA Biosciences \| DeFloria
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity method ownership percentage								50.00%
DeFloria
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding (in shares) \| shares								400,000
Change in fair value of financial instruments			$ (800)
Investment in unconsolidated entity			$ 10,200				$ 11,000
DeFloria \| Common Class A
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares) \| shares								865,052
Warrants exercise price (in cad or usd per share) \| $ / shares								$ 2.89
DeFloria \| British American Tobacco
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Preferred units outstanding (in shares) \| shares								200,000
Capital contributed								$ 10,000
Payment for convertible debt	$ 3,000
DeFloria \| AJNA Biosciences
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding (in shares) \| shares								400,000

FAIR VALUE MEASUREMENT - Investment in Unconsolidated Entity (Details) - DeFloria	Mar. 31, 2024 year	Dec. 31, 2023 year
Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	6.0	6.3
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	0.750	0.700
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	0.042	0.039
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	0	0
Discount for lack of marketability
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Joint venture, measurement input	0.200	0.200

FAIR VALUE MEASUREMENT - Fair Value Measure Inputs Debt Interest Rate Conversion Option (Details) - Level 3	Mar. 31, 2024	Dec. 31, 2023
Stated interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.050	0.050
Adjusted interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.015	0.015
Implied debt yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.128	0.110

FAIR VALUE MEASUREMENT - Schedule of Level 2 Fair Value Measurements (Details) - Level 2	Mar. 31, 2024 CAD ($)	Dec. 31, 2023 CAD ($)
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.879	0.874
Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	5.6	5.9
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.042	0.039
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0	0
Value of underlying share
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.28	0.27
Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	2.00	2.00

FAIR VALUE MEASUREMENT - Fair Value Measurement Inputs - Purchase Option (Details)	Mar. 31, 2024	Dec. 31, 2023
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	1.250	1.250
Expected term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	1.9	2.2
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	0.046	0.042
Weighted average cost of capital
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option, measurement input	0.509	0.506

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Harvested Hemp and seeds	$ 8,736	$ 9,300
Raw materials	10,637	9,726
Finished goods	6,668	6,320
Inventory, gross	26,041	25,346
Less: inventory provision	(3,554)	(3,808)
Inventories, net	$ 22,487	$ 21,538

LICENSE AND MEDIA RIGHTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jan. 29, 2024	Dec. 31, 2023
Other Commitments [Line Items]
Licensed Properties	$ 14,614			$ 14,589
License and media rights	4,000			$ 4,982
Licensing Agreements
Other Commitments [Line Items]
Amortization	974	$ 1,824
Major League Baseball Properties Inc
Other Commitments [Line Items]
Collaborative arrangement rights and obligations milestone payments payable			$ 23,000
Major League Baseball Properties Inc \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Payments for license fee	$ 2,500	$ 2,000
Additional maturities period	2 years

LICENSE AND MEDIA RIGHTS - Schedule of License Liability Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Other Commitments [Line Items]
Less: Current license liabilities	$ (5,072)	$ (9,852)
Total non-current license and media rights payable	13,899	$ 11,338
Licensing Agreements
Other Commitments [Line Items]
2024 (9 months remaining)	2,500
2025	5,500
2026	6,000
2027	6,500
Total payments	20,500
Less: Imputed interest	(1,529)
Total license and media rights payable	18,971
Less: Current license liabilities	(5,072)
Total non-current license and media rights payable	$ 13,899

LICENSE AND MEDIA RIGHTS - Schedule of Expected Amortization of Licensed Properties (Details) - Licensing Agreements $ in Thousands	Mar. 31, 2024 USD ($)
Other Commitments [Line Items]
2024 (9 months remaining)	$ 2,923
2025	3,897
2026	3,897
2027	3,897
Total future amortization	$ 14,614

DEBT - Narrative (Details) - BAT Group $ / shares in Units, $ in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 $ / shares	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Nov. 14, 2022 CAD ($) $ / shares	Nov. 14, 2022 USD ($)
Line of Credit Facility [Line Items]
Debt instrument, convertible, ownership percentage of shares						19.90%	19.90%
Debt instrument, convertible, conversion price \| $ / shares						$ 2.00
Minimum
Line of Credit Facility [Line Items]
Debt instrument, annual increase, accrued interest						5.00%	5.00%
Maximum
Line of Credit Facility [Line Items]
Debt instrument, annual increase, accrued interest						1.50%	1.50%
Convertible Notes Payable
Line of Credit Facility [Line Items]
Principal Amount				$ 59,544	$ 60,116	$ 75.3	$ 56,800
Debt instrument, convertible, ownership percentage of shares				19.90%
Debt instrument, convertible, conversion price \| $ / shares			$ 2.00
Foreign currency gain \| $	$ 925	$ 12
Interest payable \| $				$ 3,915	$ 3,182

DEBT- Schedule of Convertible Debenture (Details) - BAT Group - Convertible Notes Payable $ in Thousands, $ in Millions	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Nov. 14, 2022 CAD ($)	Nov. 14, 2022 USD ($)
Line of Credit Facility [Line Items]
Principal Amount	$ 59,544	$ 60,116	$ 75.3	$ 56,800
Unamortized Debt Discount and Costs	(16,808)	(17,588)
Net Carrying Amount	$ 42,736	$ 42,528

DEBT - Schedule of Interest Expense (Details) - BAT Group - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Line of Credit Facility [Line Items]
Interest expense	$ 733	$ 697
Amortization of debt discounts and costs	401	319
Total interest and amortization expense	$ 1,134	$ 1,016

LEASES - Narrative (Details)	Mar. 31, 2024
Lessee, Lease, Description [Line Items]
Renewal term	5 years
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year 4 months 31 days
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	11 years

LEASES - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
2024 (9 months remaining)	$ 2,449
2025	2,892
2026	2,169
2027	1,844
2028	1,762
Thereafter	11,884
Total lease obligation	23,000
Less: Imputed interest	(5,598)
Total lease liabilities	17,402
Less: Current lease liabilities	2,339	$ 2,252
Total non-current lease liabilities	$ 15,063	$ 15,655

LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net loss	$ (9,634)	$ (2,912)
Weighted-average number of common shares - basic (in shares)	156,036,670	152,314,150
Dilutive effect of stock options and awards (in shares)	0	0
Weighted-average number of common shares - diluted (in shares)	156,036,670	152,314,150
Loss per common share - basic (in usd per share)	$ (0.06)	$ (0.02)
Loss per common share - diluted (in usd per share)	$ (0.06)	$ (0.02)

LOSS PER SHARE - Schedule of Potentially Dilutive Awards (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive awards (in shares)	9,272,942	6,602,237
Outstanding options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive awards (in shares)	5,522,942	4,386,215
Outstanding restricted share units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive awards (in shares)	3,750,000	2,216,022

LOSS PER SHARE - Narrative (Details) - BAT Group - $ / shares	Mar. 31, 2024	Nov. 14, 2022
Line of Credit Facility [Line Items]
Debt instrument, convertible, ownership percentage of shares		19.90%
Debt instrument, convertible, conversion price (in cad per share)		$ 2.00
Convertible Notes Payable
Line of Credit Facility [Line Items]
Debt instrument, convertible, ownership percentage of shares	19.90%
Debt instrument, convertible, conversion price (in cad per share)	$ 2.00

SHARE-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	0
Options outstanding, weighted average grant-date fair value (in usd per share)		$ 0.56
Exercised (in shares)	0	0
Fair value of shares vested	$ 869	$ 740
Share-based compensation expense	842	$ 375
Unrecognized share based compensation expense	$ 1,783
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Prescribed service period	4 years
Unrecognized share based compensation expense, period for recognition	2 years 3 months
Restricted share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

SHARE-BASED COMPENSATION - Schedule of Inputs used in Valuation of Awards (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	89.50%
Risk-free interest rate	3.40%
Expected dividend yield	0.00%
Value of underlying share (in usd per share)	$ 0.56
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 6 months

SHARE-BASED COMPENSATION - Schedule of Detail of the Number of Stock Options Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Number of Options
Outstanding (in shares)	5,780,134
Granted (in shares)	0
Exercised (in shares)	0	0
Forfeited (and expired) (in shares)	(257,192)
Outstanding (in shares)	5,522,942		5,780,134
Exercisable/vested (in shares)	2,761,000
Weighted- Average Exercise Price per Option
Outstanding (in usd per share)	$ 0.77		$ 0.75
Granted (in usd per share)	0
Exercised (in usd per share)	0
Forfeited (and expired) (in usd per share)	0.53
Outstanding (in usd per share)	0.77		$ 0.75
Exercisable/vested (in usd per share)	$ 1.06
Weighted- Average Remaining Contract Term (in years)
Outstanding	8 years 3 months 21 days		8 years 6 months 21 days
Exercisable/vested	7 years 4 months 20 days
Aggregate Intrinsic Value
Outstanding	$ 0		$ 0
Exercisable/vested	$ 0

SHARE-BASED COMPENSATION - Schedule of Details of the Number of Restricted Share Awards Outstanding (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Number of Shares
Outstanding (in shares) \| shares	7,250,766
Granted (in shares) \| shares	0
Forfeited (in shares) \| shares	(85,731)
Vested (in shares) \| shares	(2,895,489)
Shares withheld upon vesting (in shares) \| shares	(519,546)
Outstanding (in shares) \| shares	3,750,000
Weighted- Average Grant Date Fair Value
Outstanding (in usd per share) \| $ / shares	$ 0.31
Granted (in usd per share) \| $ / shares	0
Forfeited (in usd per share) \| $ / shares	0.53
Vested (in usd per share) \| $ / shares	0.30
Shares withheld upon vesting (in usd per share) \| $ / shares	0.53
Outstanding (in usd per share) \| $ / shares	$ 0.29

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 16	$ 0
Effective tax rate	(0.20%)	0.00%
Federal income tax rate	21.00%	21.00%

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands					3 Months Ended		12 Months Ended
	Feb. 12, 2024	May 01, 2023	Mar. 02, 2021	Nov. 30, 2020	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2021	Apr. 06, 2023
Related Party Transaction [Line Items]
Purchase option			$ 8,000				$ 8,000
Revenue					$ 12,124	$ 17,010
DeFloria
Related Party Transaction [Line Items]
Warrants outstanding (in shares)								400,000
DeFloria \| British American Tobacco
Related Party Transaction [Line Items]
Preferred units outstanding (in shares)								200,000
Capital contributed								$ 10,000
Payment for convertible debt	$ 3,000
DeFloria \| AJNA Biosciences
Related Party Transaction [Line Items]
Warrants outstanding (in shares)								400,000
Related Party
Related Party Transaction [Line Items]
Note receivable				$ 1,000
Note receivable interest rate		8.00%		3.25%
Related Party \| Notes Receivable
Related Party Transaction [Line Items]
Other assets		$ 170			113
Financing receivable, term		36 months
Related Party \| Service Agreements \| DeFloria
Related Party Transaction [Line Items]
Revenue					311
Accounts receivable					$ 74

Charlottes Web (QX) (USOTC:CWBHF)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Charlottes Web (QX) Charts.

Charlottes Web (QX) (USOTC:CWBHF)
Historical Stock Chart
From May 2023 to May 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CWBHF Charlottes Web Holdings Inc (QX)

Latest CWBHF Messages

Loading Messages....

Charlottes Web Holdings Inc (QX) News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CWBHF Charlottes Web Holdings Inc (QX)

Latest CWBHF Messages

Loading Messages....

Charlottes Web Holdings Inc (QX) News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App